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Abstract 
Around 500 million cases of four of the major curable sexually transmitted infections 
(STIs), Chlamydia, gonorrhoea, syphilis and trichomoniasis, were recorded worldwide in 
2008, an increase of 11% from 2005, confirming the need for improved prevention and 
treatment strategies. The chances of acquiring these infections are 8 times greater in 
women than men because of biological, social and cultural factors. Furthermore, the 
presence of these infections increases the chances of both acquisition and transmission of 
HIV/AIDS by causing genital ulcers and inflammation in the vagina. 
   
The human vagina is considered to be a novel, non-invasive and safe route for drug 
delivery because of its rich blood supply, large surface area and low enzymatic activity. 
There are many vaginal preparations available in the market but conventional systems 
such as creams and gels are criticised because of messiness and leakage, and many 
vaginal formulations have the disadvantage of daily dosing. Intravaginal rings (IVRs) have 
potential advantages over other delivery systems, in that they can be used for prolonged 
periods of time, avoid messiness and sustained drug delivery is possible. Previous 
research has focussed on the use of IVRs for the prevention of HIV. This thesis describes 
the development of IVRs for the treatment of vaginal bacterial and fungal infections, 
including STIs.  
 
The most important component of IVRs is the polymer used in their construction; 
currently IVRs are composed of silicone and polyethylene vinyl acetate but these require a 
high processing temperature and are suitable only for delivery of low molecular weight, 
hydrophobic drugs. In this thesis, the use of polycaprolactone (PCL) as a potential polymer 
for use in IVRs is investigated because of its perceived advantages over other polymers, 
such as low processing temperature and potential to deliver a wide range of drug 
molecules from hydrophobic to hydrophilic, and low-molecular to high molecular weight. 
 
 Following a review of the literature in Chapter 1, the delivery of metronidazole using 
PCL, which could be used for the treatment of bacterial vaginosis, is considered in Chapter 
2. Delivery of metronidazole in an IVR could be a better option than the vaginal gel and 
oral tablet formulations that are currently available because an IVR would provide long 
term sustained delivery and would be expected to reduce the gastrointestinal side effects 
associated with oral delivery. PCL matrices loaded with different concentrations of 
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metronidazole achieved an incorporation efficiency of 40-54%. The matrices were studied 
using a range of approaches including release into simulated vaginal fluid (SVF), 
morphological and drug distribution studies, thermal characterization and antibacterial 
activity against Gardnerella vaginalis (one of the main bacteria implicated in bacterial 
vaginosis). First day burst release occurred due to the presence of drug crystals at the 
surface of the PCL which was confirmed by scanning electron microscopy and Raman 
microscopy. Even considering the small decrease in antibacterial activity that was 
measured during the 14 day test period, drug release on each of the 14 days was greater 
than the minimum inhibitory concentration (MIC) against G. vaginalis. The effect of 
polyethylene glycol (PEG) addition on drug release and mechanical properties of the PCL 
was then investigated. Different concentrations of PEG were loaded into PCL matrices 
along with 10% w/w metronidazole. Increasing the concentration of PEG enhanced both 
drug loading and the amount of daily drug release, but this was associated with a negative 
effect on the mechanical properties of polymer and made it more soft and brittle. It was 
concluded that PCL has potential to be a useful polymer for use in IVR delivery of 
metronidazole but that there was still capacity to improve drug loading. 
 
 Chapter 3 describes experiments with PCL matrices loaded with doxycycline, 
which can be used for the treatment of gonorrhoea and Chlamydia. A slight alteration to 
the method of production of PCL matrices enabled 100% drug loading to be obtained. 
Following the same suite of tests described for Chapter 2, it was concluded that these PCL 
matrices can deliver doxycycline effectively for 14 days, and the concentrations released in 
vitro on each of the 14 days were greater than the minimum inhibitory concentration (MIC) 
against several pathogens that are sexually transmitted. Additionally, the toxicity of PCL 
leachates was tested on the vaginal cell line VK2/E6E7 and found to be safe for vaginal 
delivery. There are currently no commercial vaginal preparations of doxycycline so this 
study could be useful in introducing a new drug delivery system for doxycycline through 
the intravaginal route.  
 
 In Chapter 4, the ability of PCL to deliver a combination of drugs is investigated. 
Metronidazole and doxycycline are the combination involved, which are used together for 
the treatment of pelvic inflammatory disease. PCL matrices loaded with different 
concentrations of metronidazole and doxycycline were tested for in vitro drug release, 
morphological, thermal and antibacterial testing to investigate whether the combination 
compromised the effectiveness of the PCL matrix in drug delivery. Excellent drug loading 
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of both drugs was obtained, and the concentrations released for each of 14 days were 
associated with a high level of antibacterial activity. This is the first investigation of the 
vaginal delivery of metronidazole and doxycycline in combination. 
  
The delivery of a macromolecular protein using PCL matrices is investigated in 
Chapter 5. This study is based on the fact that vaginal vaccination is potentially a more 
effective means of eliciting a strong localized immune response against HIV, in 
comparison to conventional intramuscular or intranasal routes of administration, and most 
of these vaccines are either proteins or peptides in nature. Lactoferrin was used as a 
model protein for the study because of its reported activity against herpes simplex virus, 
Chlamydia trachomatis and HIV. PCL matrices proved suitable for the delivery of 
lactoferrin; the integrity of the protein was retained as shown using SDS-PAGE of the 
protein following loading into PCL and release into SVF.  
 
These findings could provide a breakthrough in the field of vaginal drug delivery for 
the treatment of STIs and could also reduce the risk of HIV infection. Using PCL matrices 
in intravaginal rings for vaginal delivery of microbicides as a strategy to treat vaginal 
infections and STIs is expected to reduce the risks of drug resistance, treatment failure 
and gastrointestinal adverse effects associated with long-term oral drug delivery, by 
improving compliance with treatment duration and avoiding systemic adverse drug 
reactions. Future research should investigate the mechanical properties of PCL, which 
may limit the preparation of simple IVRs, and consider the use of drug-loaded PCL as 
inserts within a flexible inert IVR, or covering the drug-loaded PCL IVR with a flexible inert 
material with delivery windows that allow drug release. Mixing PCL with a second polymer 
such as polyethylene may also be considered but it would be important not to destroy the 
usefulness of PCL in terms of its low processing temperature.  
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1. Abstract  
This review describes the intended use of polycaprolactone (PCL) for the preparation of 
intravaginal rings (IVRs) that may be used for vaginal delivery of antibacterials in the 
treatment of curable sexually transmitted infections (STIs). PCL has certain characteristics 
(biocompatibility, permeability and low processing temperature) that are advantageous 
when compared to polymers that are currently used in the production of IVRs such as 
silicone and polyethylene vinyl acetate. Vaginal drug delivery using IVRs has several 
advantages over other routes of administration because drug delivery can occur over a 
long period of time from a single ring, first pass metabolism is bypassed, and rings are 
generally regarded as comfortable and acceptable to use. Curable STIs are a major 
concern because of their increasing number and their adverse effect on the health. Current 
treatments, involving creams, gels and pessaries, required daily administration and can be 
messy, leading to relatively low acceptability. There are several recent review articles 
published on the topic of IVRs but most of these articles concentrate on the use of rings in 
HIV/AIDS prevention or as contraceptives. Little attention has previously been given to the 
use of IVRs for the delivery of antibacterials for the treatment of curable STIs. This review 
highlights the potential use of IVRs for the treatment of curable STIs, explains the 
advantages of these delivery systems over other solid and semi-solid vaginal preparations, 
and considers the potential benefits of PCL as a polymer for vaginal drug delivery.   
2.  Introduction 
Most treatable vaginal infections are sexually transmitted (STIs, Table 1), but while these 
are the major focus of this review some consideration is given to certain infections that are 
not caused by sexual activity but are important in vaginal infections such as bacterial 
vaginosis and candidiasis. There are several recent review articles published about IVRs 
but the articles concentrate on their use as a prevention strategy for HIV/AIDS or their use 
as contraceptives. STIs are of considerable concern globally due to their adverse effect on 
quality of life, pregnancy-related complications, burden to the economy and the fact that 
they are increasing in prevalence globally1. Additionally, the presence of many untreated 
STIs and an unhealthy vaginal system increases the risk of both acquisition and 
transmission of HIV due to i) genital ulceration which facilitates entry of HIV through 
breaks in the vaginal epithelia2 ii) inflammation caused by the STIs which attracts various 
types of cells such as CD4+ and T-cells that are primary targets of HIV2 and iii) increase in 
vaginal pH which reduces the vaginal defence against pathogens3. The most common 
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symptoms associated with STIs are vaginal infections, vaginal discharge and cervicitis 
(Figure 1) which can cause disturbance in vaginal environment and can make it 
susceptible to other infections. 
Table 1: Common causes of sexually transmitted and vaginal infections4-6 
STI Cause 
Bacterial Infections 
   Gonorrhea 
   Chlamydia 
   Chancroid 
   Donovanosis 
   Mycoplasma 
   Syphilis 
Neisseria gonorrhoeae 
Chlamydia trachomatis 
Haemophilus ducreyi 
Klebsiella granulomatis 
Mycoplasma genitalium 
Treponema pallidum 
Viral Infections 
   Acquired immunodeficiency syndrome 
   Genital herpes 
   Genital warts 
Human immunodeficiency virus 
Herpes simplex 1 & 2 
Human papillomavirus 
Protozoa 
   Trichomoniasis Trichomonas vaginalis 
Fungal 
   Candidiasis Candida albicans 
Parasitic Infections 
   Scabies 
   Pubic lice 
Sarcoptes scabiei 
Phthirus pubis 
Other vaginal infections 
   Bacterial vaginosis Polymicrobial (Gardnerella 
vaginalis, Prevotella spp., 
Mobiluncus spp., Ureaplasma 
urealyticum and Mycoplasma 
homonis)  
 
 
Figure 1: Schematic representation of the most important symptoms and causes of 
sexually transmitted infections (STIs) and vaginal infections 
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In 2012, a WHO report indicated that four major curable STIs had increased in number by 
11.3% worldwide within 3 years1. Although this doesn’t incorporate the concomitant 
increase in global population, as most of the diseases can be asymptomatic so the 
numbers may be an underrepresentation.  
The chances of male to female transmission of STIs is 8 times higher than the female to 
male transmission and that may be due to social, cultural and biological factors4. STIs and 
their reoccurrences are preventable and there are many health promotion activities trying 
to prevent these infections in a cost effective way. However, the long duration of treatment 
and side effects associated with the prescribed drugs, usually given by the oral or 
parenteral route, make the therapy uncomfortable for the patients. Consequently, non-
adherence to the treatment regimen is a major problem, which leads to repetitive episodes 
of STIs and development of resistance to many drugs5. WHO considers non-adherence to 
be an alarming factor and addresses the need for adherence to therapy6. 
3. The vagina as a route for drug delivery  
The vagina is considered to be a favourable site for both local and systemic delivery of 
drugs because of its large surface area and permeability to a large variety of compounds 
such as prostaglandins and steroids4. The vaginal epithelium has relatively few blood 
vessels so topical drug delivery for local action can be effective. For example the topical 
intravaginal delivery of microbicides results in high concentrations in the genital 
compartment rather than than systemic circulation7. It may also be a favourable site for the 
administration of peptides and proteins targeting the mucosal immune system8. Another 
option is as a site for systemic delivery; as the GI lumen and the liver are the primary sites 
of elimination for many compounds, vaginal administration may be preferable to the oral 
route due to avoidance of both gastrointestinal absorption and the hepatic first pass effect. 
Orally delivered drugs may cause side effects such as vomiting, and drug-drug or drug-
food interference can also affect drug absorption9. Consequently, vaginal administration 
can be more convenient in terms of allowing more prolonged dosing, lower exposure to 
drugs and continuous drug delivery10. Other advantages of intravaginal drug delivery 
systems are rapid drug absorption and quick onset of action, and self-administration. 
3.1  Vagina anatomy and physiology 
The human vagina (Figure 2) extends from the uterus, and is situated behind the bladder 
and in front of the rectum; it is directed upward and backward, its axis forming an angle of 
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over 90° with the uterus, opening forward. It may be described as a fibromuscular tube 
approximately 7-10 cm in length. The position and size of the vagina play an important role 
in designing a vaginal drug delivery product. For example, vaginal gels have the 
disadvantage of leakage particularly due to the angle of the vagina, and the dimension of 
the vagina must be considered when determining the dimensions of intravaginal rings 
(IVRs). 
 
Figure 2: Anatomy of the human vagina11 
Vaginal histology is composed of four distinct layers (Figure 3): 
1. The non-secretory stratified squamous epithelium forms the superficial layer. This layer 
can be divided into different classes according to the stage of maturation: basal, 
parabasal, intermediate and superficial. During maturation, cells move from the basal layer 
to the superficial layer, becoming flatter, with small nuclei and a larger cell volume. The 
thickness of cervical squamous epithelium varies from (0.2 to 0.5 mm) and depends on the 
age12. 
2. The lamina propria, or tunica, made of collagen and elastin, contains vascular and 
lymphatic channels. 
3. The muscle layer comprises smooth muscle fibres running in both circular and 
longitudinal directions and contains a rich blood supply.  
4. The final layer called tunica adventitia consists of areolar connective tissue and a large 
plexus of blood vessels.  
The elasticity of the vagina is due to the presence of smooth elastic fibres in the muscular 
layer and the loose connective tissue of the tunica adventicia13. 
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Figure 3: Histology of the vagina. 1: capillary vessels; 2: artery; 3: vein14 
The surface of the vagina is composed of numerous folds or rugae. The rugae provide 
support, distensibility, and an increased surface area of the vaginal wall. Blood is supplied 
to the vagina by the networks of blood vessels extending from the internal iliac artery, 
uterine, middle rectal and internal pudendal arteries12. The lower part of vagina receives its 
nerve supply from the pudendal nerve and from the inferior hypogastric and uterovaginal 
plexus. The upper part of the vagina has much fewer sensory fibres making it relatively 
insensitive, which is the reason women can’t feel the presence of IVRs, tampons and 
pessaries inside the vagina15.  
3.2  Vaginal defence mechanisms  
3.2.1 Vaginal epithelium 
The superficial layer is the stratified squamous epithelium (Figure 3), which is the primary 
vaginal defence mechanism as it sheds continuously, making it difficult for microorganisms 
to invade the basement tunica adventitia16. Additionally, vaginal fluids spread over the wall 
of the vaginal epithelium to form a protective layer that serves as a barrier for the invading 
bacteria to protect the vagina from infection. 
3.2.2 Bacterial flora 
The microorganisms present depends upon the physiological conditions of the vagina, 
which further depend on other factors such as age, time of the menstrual cycle, 
pregnancy, menopause, infection and douching practices. The vaginal microflora consists 
of both gram-positive and gram-negative species for both cocci and bacilli17. Lactobacilli, 
which are gram-positive bacteria, are beneficial for vaginal health because they compete 
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with exogenous microbes for nutrients. Conversion of glycogen present in exfoliated cells 
into lactic acid by these microorganisms helps to maintain the pH of the vagina18. 
Lactobacilli may or may not produce hydrogen peroxide H2O2 depending on the strain. 
H2O2 is toxic to other microorganisms that produce little or no H2O2 scavenging enzyme 
such as catalase. An absence of H2O2 producing lactobacilli in the normal vaginal flora can 
result in bacterial vaginosis or an overgrowth of catalase–negative organisms18.  
3.2.3 Immune cells   
Protective immunity against pathogens is provided by both cellular and humoral systems. 
Langerhans cells are present in the lumen of the vagina and provide local immunity19. 
These cells can pass antigens to the dendritic cells that migrate to the lymph nodes, where 
they activate B and CD4+ T cells. These activated B lymphocytes return to the 
subepithelium and turn into IgA secreting cells and, along with IgG, IgM and IgA antibodies 
present in the cervical mucus, act as a defence mechanism for the vagina20. 
4. Vaginal drug absorption 
There are some drug properties that affect their absorption such as molecular weight, 
oil/water partition coefficient and ionic character21. As the wall of the vagina is made up of 
epithelial tissues, absorption through the vagina is similar to that of other epithelial tissues 
and can be best explained by the fluid mosaic model as a hydrophobic lipid layer 
interspersed with aqueous pores22. The transport mechanism of most vaginal absorbed 
substances is simple diffusion. Lipophilic substances are absorbed through the 
intracellular pathway, whereas hydrophilic substances are absorbed through the 
intercellular pathway or across aqueous pores present in the vaginal mucosa23. 
4.1 Factors affecting vaginal drug absorption 
There are a number of factors worth considering in terms of drug absorption from the 
vagina. Firstly, due to the anatomical position of the vagina some liquid and semisolid 
preparations may be expelled under the influence of gravity, resulting in leakage. 
Secondly, the vaginal epithelium undergoes cyclic changes, under the influence of 
hormones such as oestrogen, progesterone, luteinising hormone, follicle stimulating 
hormone and the different phases of the menstrual cycle24. In the late follicular phase, the 
epithelium thickness is increased due to the proliferation of the cells in the basal layer, 
stimulated by oestrogen and at the same time the number of intercellular junctions also 
increases with narrow intercellular channels. In the luteal phase, there is desquamation of 
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the superficial epithelial layer so that epithelium becomes loose with the widening of the 
intercellular channels. In this case, there is a possibility of absorption of high molecular 
weight hydrophilic drugs25. Thirdly, vaginal pH also influences the drug absorption. Since 
many drugs are weak electrolytes, the pH may change their degree of ionization and, 
therefore, affect absorption. For example in vitro studies have shown that the release of 
prostaglandinE2 from vaginal preparations may vary depending on the pH of the media26, 
and diffusion of nonoxynol 9 into cervical mucus is pH dependent13. 
4.2  Vaginal systemic drug delivery 
There are a number of examples of the study of drug administration via the vagina for 
systemic delivery: 
 The steroids estradiol, estrone, progesterone, medroxy progesterone acetate, 
norgestrel, norethisterone and testosterone can all be successfully absorbed through 
the vaginal wall, as shown by measurement of systemic levels of these drugs in 
humans. Steroids with greater lipophilicity (such as progesterone and estrone) show 
more rapid absorption than those with less lipophilicity (such as hydrocortisone and 
testosterone)10. A lactose based progesterone vaginal tablet has been designed to 
deliver biologically effective amounts of progesterone for up to 48 h. When 
administered into the vagina these tablets form a milky suspension and provide 
advantages for the treatment of menstrual irregularities, functional uterine bleeding, 
luteal phase defects, premenstrual tension, infertility and osteoporosis27.  
 Intravaginal delivery of indomethacin has been investigated for the treatment of 
preterm labour. Indomethacin, a potent inhibitor of prostaglandin synthesis and has 
been used effectively as a labour inhibiting agent for 48 h in pregnancies of less than 
32 weeks. Indomethacin has been proven to be more effective when used intra-
vaginally as compared to an intrarectal plus oral regimen, whereby delivery of the baby 
was delayed by more than 7 days in 78% of women who received the drug 
intravaginally compared with 43% who received the same dose rectal-orally28.  
 Intravaginal metronidazole administration has been investigated for systemic delivery. 
A solution at 10 mg/kg administered either orally or intra-vaginally to rats indicated that 
absorption of metronidazole from the vagina was rapid, with only 4% of the dose 
remaining in the vagina after 4 h29.  
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 Systemic distribution of insulin has been demonstrated following absorption from the 
vagina in rats and rabbits, so this may be a potential alternative route for delivery of 
currently available, ‘injection-only’ biopharmaceuticals30. Insulin is a hydrophilic 
molecule that is absorbed through intercellular aqueous channels; hence, absorption 
would be greater when the epithelium is thinner or by using a penetration enhancer. It 
has been found that there is an increase in hypoglycaemia in rats when insulin was 
administered vaginally using effective enhancer such as sodium taurodihydrofusidate 
and polyoxyethylene-9-lauryl ether31.  
DNA-based vaccines are being investigated to overcome the deficiencies of antigen-based 
vaccines for the treatment of HIV and vaginal mucosa was considered as one of the 
effective routes of administration32. 
4.3  Vaginal local drug delivery 
Drugs are often required to be effective locally and with minimal systemic absorption. 
 In a study in patients with vaginal rhabdomyosarcoma and residual vaginal disease 
following surgery and chemotherapy, the effect of high-dose irradiation from vaginal 
moulds loaded with iridium were examined and it was found that patients treated with 
these vaginal preparations remained well and disease free for 7 years33.  
 A number of studies have investigated the local delivery of antimicrobial agents. 
Chitosan/alginate complexes have been investigated for the preparation of vaginal 
inserts containing chlorhexidine digluconate for local treatment of genital infections. On 
the basis of insert water uptake and chlorhexidine digluconate release, inserts based 
on the complex CH/ALG(1:9) were found to provide the optimum drug release with the 
efficiency to kill the principal pathogens responsible for aerobic vaginitis and 
candidiasis34. Liposomal local vaginal delivery of acyclovir, metronidazole and 
clotrimazole in the form of bioadhesive gels can provide an excellent means for 
treatment of vaginal infections35,36. In an investigation on the local delivery of 
itraconazole, bioadhesive film made up of hydroxypropylmethyl cellulose and 
hydroxypropyl cellulose based system it has been reported that these films were able 
to deliver the drug successfully for 8 h. During lactobacillus and cytotoxicity studies it 
has been concluded that bioadhesive films can be used intravaginally without affecting 
cell viability of the vaginal mucosa37. In a clinical study on 136 patients, it has been 
found that single application of butoconazole 2% cream for the treatment of vaginal 
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candidiasis was more effective than the fluconazole 150 mg oral tablets to get the relief 
from the signs and symptoms of vaginal candidiasis compared38. 
 Local delivery of lyophilized Lactobacillus sporogenes in the form of a vaginal 
suppository has been recently studied as a candidate for probiotic prophylaxis and 
treatment of vaginal infections by restoring the natural vaginal flora to a healthy state. 
The cocoa butter suppositories used in the experiment dissolved at the application site 
at the body temperature and the without affecting the viability of Lactobacillus 
sporogenes39.  
Table 2: Intravaginal formulations available in the market for the treatment of STIs 
and vaginal infections 
Vaginal 
formulations 
Brand name Active ingredients Intended use 
Gels and creams Femstat 
Gynazol 1 
Mycelex 3 
Gyne-Lotrimin 
Gynex 
Trivagizole 
Monistat 
Leader miconazole 1 
Terazol 
Vagistat 
Sporanox 
Diflucan 
Nilstat 
Econate VT 
Flagystatin 
 
 
 
Metrogel 
Metrocream 
Vandazole 
Vivagel 
Butaconazole 
 
Clotrimazole 
 
 
 
Miconazole 
 
Teraconazole 
Tioconazole 
Itraconazole 
Fluconazole 
Nystatin 
Econazole 
Metronidazole+ 
Nystatin 
 
 
Metronidazole 
 
 
SPL7013, or 
astodrimer sodium 
Antifungal 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mixed infection 
(Trichomonas, 
Candida) 
Bacterial vaginosis 
Bacterial vaginosis 
Vaginal 
suppositories/ 
pessaries 
Terazole 3 
Gyno-Pevaryl 
 
Canesten 
Myclo-gyne 
Cleocin 
 
Terconazole 
Econazole nitrate 
Clotrimazole 
Adipic acid 
Clindamycin 
Antifungal 
 
 
 
 
Bacterial vaginosis 
Vaginal ovule Gynecure 
Flagystatin 
Tioconazole 
Metronidaole+ 
Nystatin 
Antifungal 
Trichomonas & 
Candida infection 
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5. Vaginal formulations 
Vaginal drug delivery formulations span the spectrum from semi-solids to solid dosage 
forms and are capable of short-term drug delivery over several hours (Table 2) to 
sustained release over several months (intravaginal rings, Table 3). Some of these 
conventional preparations are criticised due to their inconvenience of multiple days of drug 
dosing (vaginal tablets), messiness and leakages (vaginal creams and gels), the 
requirement of applicators and sometimes if any product with reduced or single-day 
treatment is used then it may contain increased drug concentration. 
6. Intravaginal rings 
Intravaginal rings (IVRs) are flexible, elastomeric devices of approximately 5.5 cm in 
diameter and a cross-sectional diameter of 4-9 mm. These rings offer long-term controlled, 
sustained drug delivery, which is advantageous over other conventional vaginal drug 
delivery. The controlled delivery of microbicides from IVRs is also advantageous over 
semi-solid vaginal formulations, for their longer duration, and reduced frequency self-
administration, which increases the adherence of patients to their treatment regimen. IVRs 
are widely used for contraception (Table 3), with high levels of efficacy and user 
acceptability40. There are very few chances of clinically significant lesions with IVRs and 
women have a greater preference for IVRs with applicators and a one size fit-free 
diaphragm for drug delivery41. Other than the commonly available IVRs (Table 3) a few 
other IVRs for the prevention of HIV are under development (Table 4). 
Table 3: Intravaginal rings that are commercially available 
Name of ring Active ingredients Polymer used      Uses 
Nuvaring® Etonogestrel + ethinyl 
estradiol 
Polyethylene-co-
vinyl acetate 
Contraception 
Femring® Estradiol-3-acetate Silicone Relief of vaginal and 
urogenital symptoms in 
menopausal women 
Estring® Estradiol Silicone Relief of vaginal and 
urogenital symptoms in 
menopausal women 
Progering® Progesterone Silicone Contraception in lactating 
women 
Fertiring® Progesterone Silicone Contraception 
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In general, IVRs avoid the multiple days of dosing and avoid messiness and leakage 
associated with conventional systems such as creams and gels42. Some disadvantages do 
exist, however, such as the potential for the expulsion of rings, discomfort due to the 
feeling of an exogenous material inside the vagina and occasional side effects such as 
bleeding and itching. So before designing a new IVR careful consideration of dimension to 
reduce the chances of expulsion and suitable choice of polymer is very important to 
minimise the discomfort cause by these IVRs. 
6.1  Types of intravaginal rings 
6.1.1 Matrix rings 
This is the most common and simple design of an IVR, in which drug particles are 
dispersed uniformly throughout the polymer (Figure 4A). The drug particles present on the 
surface dissolve when it comes to contact with vaginal fluid. With time, vaginal fluid enters 
the pores and channels formed when drug molecules dissolve and further release takes 
place. As drug release takes place, the thickness of the zone of drug depletion increases 
and the diffusion path length for the rest of the drug increases, which leads to decrease in 
drug release with time. The drug release behaviour for this type of ring system can be best 
explained by the Higuchi equation43-45, 
𝑄 = (𝐷𝑝 [2𝐴 − 𝐶𝑝]𝐶𝑝 𝑡) 0.5 
where Q is cumulative release per unit surface area (mg/cm2), Dp is the drug diffusion 
coefficient in the polymer (cm2/day), A is the drug loading per unit volume in the polymer 
(mg/cm3), Cp is the drug solubility per unit volume in the polymer and t is time (days)43.  
6.1.2 Reservoir vaginal rings 
In this type of design, a non-medicated polymeric sheath surrounds a core that contains 
the drug (Figure 4B). In this type of system, the thickness of the non-medicated sheath 
controls the rate of drug release. The medicated core contains uniformly distributed drug 
which diffuses out through the non-medicated sheath with constant rate “zero order” 
release kinetics. A modification of this design is the shell-type IVR in which the drug core is 
sandwiched between a non-medicated core and outer non-medicated sheath44.  
Other than the above designs, a few other novel IVR designs have been suggested 
particularly to overcome the problem of delivery of hydrophilic, high molecular weight and 
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temperature labile drugs through hydrophobic polymers. In the modified designs, the ring 
body acts as the holder and solid dosage forms are inserted in the holder for delivery.  
6.1.3 Coated pod insert IVR 
A non-medicated polymeric ring contains coated drug pods incorporated in polymeric 
elastomer (Figure 4C). The diameters of the delivery window have a major effect on the 
drug delivery. Other factors that affect drug delivery are the polymer used for IVR 
production and the number of inserted pods46.  
6.1.4 Rod and tablet insert IVR 
This system is same as that of coated pod inserts but in this system instead of coated 
pods it contains lyophilised polymeric gel or compressed tablets47.  
6.1.5 Multi segment IVR  
This design is useful for the delivery of two or more drugs simultaneously without the need 
to mix the drugs. Drugs can be loaded individually to avoid any cross reactivity48. 
 
 
 
 
 
 
 
 
 
                                                          
Figure 4: Intravaginal ring designs: A) Matrix B) Reservoir C) Pod type. Blue colour 
represents the part of IVR loaded with drug and white colour represents without 
drug  
 
  
A C B 
Drug loaded core 
Inert outer core 
Drug loaded pods 
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IVRs have been investigated for delivery of various drugs for HIV prevention (Table 4), 
contraception or to relieve menopausal symptoms.  
Table 4: Intravaginal rings investigated for the prevention of HIV 
Drugs  Polymeric material Ring design References 
Dapivirine  Silicone 
Silicone 
Polyurethane 
Acacia gum 
Reservoir, 
Matrix 
Matrix 
Reservoir 
49 
50 
51 
52 
CMPD 167 + maraviroc Silicone Matrix 53 
MC 1220 Silicone Matrix 54 
TMC 120 + Boc-LBA 
TMC 120 + PMPA 
Acacia gum Reservoir 52 
Tenofovir Polylactide and 
polyethylene vinyl 
acetate blends 
Polyurethane 
Matrix (Rods) 
 
 
Reservoir 
55 
 
 
56 
MIV-160 Poly(ethylene-co-vinyl 
acetate 
Matrix 57 
UC781 Silicone 
Polyurethane 
Poly(ethylene-co-vinyl 
acetate) 
Matrix 
Matrix 
Matrix 
58 
59 
58 
Dapivirine + tenofovir Acacia gum 
Polyurethane 
Reservoir 
Segmented 
52 
59 
Dapivirine + maraviroc Silicone Matrix  
 
43 
 
Tenofovir + acyclovir Silicone elastomer Pod ring 60 
IQP  Polyurethane Matrix 61 
Dapivirine + darunavir Silicone Matrix 62 
Levonorgestral + tenofovir Polyurethane Segmented 48 
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6.2 Acceptability studies of intravaginal rings 
Before using IVRs for any treatment purpose it is very important to know whether the IVRs 
are acceptable by women as a treatment strategy. Many studies have been conducted to 
check the acceptability of these rings, mostly with contraceptive devices. Efficacy, 
acceptability and tolerability of contraceptive rings containing etonogestrel and ethinyl 
oestradiol were tested with 1145 women. During the study period, each woman used the 
ring for 3 weeks and it was reported that out of all the women who completed the study 
96% were satisfied with the ring, 98% of them recommended this to others and 91% 
complied with the prescribed regimen63 In a tolerability and user acceptability study of 
novel combined contraceptive IVRs for up to 13 cycles with 2015 women, 85% of women 
who completed the study were satisfied with the ring and 90% recommended it as an 
acceptable method to others and only 2.5% discontinuation was reported due to 
discomfort caused by the device40 so rejection of IVRs on the basis of discomfort is low. A 
multicentre study conducted on 1950 women involved a 21-item questionnaire regarding 
ease of use of vaginal rings, clarity of instructions, sexual comfort, satisfaction, cycle-
related characteristics and compliance etc. More than 95% of women who completed the 
study were satisfied or very satisfied and would recommend the ring to others, and the 
60% of the women who discontinued the study were satisfied or very satisfied and would 
recommend the ring to others64.   
A multicentre randomized controlled trial has been conducted on 500 women to compare 
the IVR to vaginal patch for contraception. Three cycles of use resulted in 228 of 241 
(94.6%) and 210 of 238 (88.2%) women for ring and patch respectively completing the 
study. 71% of women who used the ring planned to continue that method after the study, 
whereas only 26.5% wanted to keep using the patch65. In a comparison study with 80 
women, IVRs were compared with oral dosage form for the purpose of contraception. The 
average score for ring acceptability was 4.3 ± 0.9 out of 5 for the ring in comparison with 
the 3.6 ± 1.0 for oral contraceptives; not only were these rings more acceptable, they also 
increased the concentration of H2O2 producing lactobacilli species by 2.7 fold66. This 
means that these IVRs are not only highly acceptable in comparison to other commonly 
used vaginal products but they also strengthen the vaginal defence by increasing the 
number of vaginal lactobacilli. A review of articles on contraceptive ring use indicated that 
the rings are highly acceptable and 90% of the women under study didn’t have any 
problem with the ring and didn’t feel the ring inside the vagina67. 
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Apart from contraception, IVRs have also been studied for hormonal drug delivery for other 
purposes. An acceptability study of estradiol IVRs over vaginal creams reported that 47% 
of the 83 patients randomized to be treated with the IVRs gave the opinion 'excellent' as a 
method to relieve vaginal atrophy and dryness as compared with 6% of the 82 patients 
using a vaginal cream. 78% of patients treated with the ring answered 'good' or 'excellent' 
as compared with 40% with the cream68. In terms of studies specific to antimicrobial agent 
delivery, a smaller number of studies have been conducted. An adherence study with 405 
couples compared three different types of vaginal preparations for the delivery of a 
microbicide (diaphragm, IVRs and applicator). 52.9% of the women preferred vaginal 
rings, 36.4% preferred applicators and 10.7% selected the diaphragm69 so IVRs were the 
preferred option for drug delivery over other commonly used vaginal products for the 
delivery of microbicides. A study was performed with 157 young African women involving 
the use of placebo silicone vaginal rings for 12 weeks with the expectation for use for the 
purpose of HIV prevention. During 12 weeks, women found the IVR highly acceptable due 
to its continuous use which could allow spontaneous protection against HIV and their non-
interference with sexual intercourse. 67% of female participants were concerned about 
interference during intercourse that could be unacceptable to their partners, so using the 
right dimensions for a ring can increase confidence in IVR drug delivery by decreasing the 
probability of interference during intercourse70. This last study is important because 
acceptability of these rings in developing countries must be considered; as due to reduced 
access to healthcare facilities the chances of STI infection is greater compared to 
developed countries70, so IVRs can be a breakthrough in reducing the cost of treatment 
and decreasing the chances of reinfection. 
7. Polycaprolactone 
7.1 Polycaprolactone as a potential material for IVRs 
Polycaprolactone (PCL) was one of the earliest polymers synthesized by the Carothers 
group in the early 1930s and became commercially available. It is semi-crystalline, 
synthetic, aliphatic polyester synthesised by ring opening polymerisation of the ε-
caprolactone monomer. 
PCL is an attractive polymer for IVR production due to its flexibility and high extensibility71. 
It has an extremely low glass to rubber transition temperature (Tg) of around -60°C, which 
makes the material highly suitable for melt processing72. At room temperature, PCL is 
highly soluble in chloroform, dichloromethane, carbon tetrachloride, benzene, toluene, 
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cyclohexanone and 2-nitropropane; slightly soluble in acetone, 2-butanone, ethyl acetate, 
dimethylformamide and acetonitrile; and insoluble in alcohols, petroleum ether, diethyl 
ether and water73. PCL has been extensively used for the production microcapsules and 
matrix-type drug delivery devices by solution processing techniques due to its solubility 
properties. 
PCL can be enzymatically biodegraded by microorganisms into non-toxic products but it 
takes several months or years to degrade it completely. Biodegradation takes place by 
hydrolysis of ester linkages under physiological conditions. Hydrolytic degradation of PCL 
involves surface and bulk degradation. In surface degradation, hydrolytic cleavage of the 
polymer chain leads to the reduction in viscosity without affecting the molecular weight. In 
the second stage, bulk degradation of PCL occurs, characterised by a decrease in 
molecular weight. Once the molecular weight has decreased to 3000 Da or less PCL may 
be completely resorbed and degraded by intracellular mechanisms74. 
7.2 The application PCL in drug delivery system 
Over the last few decades, PCL polymers have been of major interest for developing a 
variety of controlled drug delivery systems in the form of nanospheres, microspheres, 
fibres and matrices75,76. PCL matrices have been produced for the delivery of hydrophilic 
drugs such as gentamicin sulphate77 and vancomicin78, hydrophobic compounds including 
progesterone79, and for the delivery of macromolecules (catalase, lysozyme and 
collagenase)80. The precipitation casting technique for PCL matrix production has been 
established for controlled release of small molecule antibacterial (gentamicin sulphate)77, 
steroids (progesterone)79 and macromolecules (inulin)81.  A layer of methanol is added to 
PCL solution containing dissolved or dispersed drug and gradual precipitation of the PCL 
phase results by solvent transport across a polymer film formed at the solution/non-solvent 
interface. The final step involves drying the resulting matrices under ambient conditions77. 
The rapid cooling technique has recently been developed for controlled delivery of 
proteins, enzymes80 and microbicides82 from PCL matrices. This technique offers 
advantages over precipitation casting or film casting/solvent evaporation approaches since 
drug particles can be dispersed effectively throughout the matrix by rapid cooling-induced 
crystallisation of the PCL phase. Particle sedimentation leading to poor drug distribution in 
the matrix is thereby avoided. Table 5 represents the various drugs loaded into PCL 
matrices and the methods used for their preparation. 
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Table 5: Drug delivery from PCL matrices 
Loaded Drugs Preparation method Time of release (days) References 
Lysozyme Rapid cooling 12 80 
Collagenase Rapid cooling 18 80 
Catalase Rapid cooling 15 80 
Lactose  Precipitation cast 
Matrices 
3 83 
77 Gentamicin sulphate 14 
Gelatin Matrices 21 83 
Progesterone Co-dissolution 10 79 
Vancomycin Microencapsulation 2 78 
Miconazole Rapid cooling 13 82 
Ciprofloxacin Rapid cooling 30 82 
Inulin Precipitation  81 
PCL could be a potential polymer for the production of IVRs because of its low processing 
temperature, biocompatible and biodegradable nature, and highly porous morphology. 
Nhung et al. previously demonstrated the use of PCL polymer for the delivery of antiviral 
agents mainly focused toward intravaginal prevention of HIV. She also considered the 
delivery of the antibacterials, ciprofloxacin and miconazole using PCL for intravaginal 
use84. The mechanical characteristics of PCL are usually reported in the literature for solid 
PCL or for the PCL scaffold22,85. However, Wang et al. reported the potential of 
microporous PCL matrices for the production of tubes for soft tissue engineering84. In the 
literature, it is evident that PCL can be used for the delivery of many drugs by using 
various processing techniques (Table 5) so the focus here is PCL as a potential material 
for the delivery of antimicrobial agents intended for the intravaginal treatment of STIs. 
8. Conclusion 
It is clear that IVRs are highly acceptable to women in terms of convenience, avoidance of 
messiness associated with creams and gels, reduced frequency of dosing and the 
personal control offered by the vaginal ring. Additionally, drug levels in the blood can be 
greater than results from orally administered preparations66 indicating that this is an option 
for systemic drug delivery. The use of these systems is still limited to contraception and 
HIV prevention so further exploration is required into their potential use in the treatment of 
other conditions. STIs, which are an exceptionally important problem for women’s health, 
could be an area in which IVRs can be used as a treatment strategy. The topical and 
19 
 
sustained release of drugs from vaginal rings can provide direct and immediate relief and 
reduce the chances of reinfection. High levels of patient acceptability increases the 
chances of completion of therapy, which would reduce the chances of developing drug 
resistance in the microorganisms. Due to disadvantages of current polymers as described 
above PCL offer many advantages as a potential polymer for the delivery of antibacterials 
for the treatment of STIs. Low processing temperature, biodegradability and 
biocompatibility offered by PCL make it a favourable polymer for the investigation of IVR.  
9. Hypothesis 
Based on the preceding literature review, the overarching hypothesis for this thesis is that 
polycaprolactone is a suitable polymer for intravaginal delivery of antibacterials against the 
organisms that cause sexually transmitted infections. 
10. Aims 
Metronidazole is one of the most prescribed medications for the treatment of bacterial 
vaginosis, and vaginal preparations of metronidazole for the treatment of bacterial 
vaginosis are already available in the market. However the creams, gels and pessaries 
require daily dosing and can leak from the vagina, so improved vaginal delivery would be 
very useful. Therefore, the first aim of this thesis is to investigate the formulation of PCL 
matrices containing metronidazole for the treatment of bacterial vaginosis. Chapter 2 
addresses this first aim, by using a published method for the preparation and loading of 
PCL matrices based on rapid cooling suspensions of drug powder in PCL solutions in 
acetone and subsequently adjusting polymer properties and drug loading by incorporating 
PEG. 
Doxycycline is a commonly prescribed medication for the treatment of STIs such as 
chlamydia, gonorrhoea, lymphogranuloma and syphilis. There are currently no studies 
focused on the delivery of doxycycline intravaginally, so the second aim of this thesis is to 
investigate the loading and delivery of doxycycline from PCL for use as an IVR (Chapter 
3). Additionally, in this chapter the biocompatibility of PCL for vaginal delivery is by 
assessed in terms of in vitro toxicity against a vaginal cell line and the normal commensal 
bacteria, Lactobacillus jensenii, in cell culture. 
The combination of metronidazole and doxycycline is the most widely accepted treatment 
for pelvic inflammatory disease. Combining of drugs with different modes of action within a 
single vaginal ring has been tried previously for HIV prevention but not for the treatment of 
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STIs. Therefore Chapter 4 addresses the third aim of the thesis, which is to load the 
combination of metronidazole and doxycycline in the PCL matrices for the treatment of 
pelvic inflammatory disease and to check the effect of the combination of drugs on 
polymeric properties, and on drug loading and release.  
Chapter 5 deals with the fourth aim of the thesis, which is to test the PCL polymer for the 
potential to deliver a macromolecule, because recently many macromolecular drugs of 
biotechnological origin have been studied for the treatment and prevention of STIs.  
In order to address the aims described above, within each of the experimental chapters a 
series of experiments are performed: 
A) To optimise the formulation conditions for PCL matrices. 
B) To characterise the matrices in terms of drug loading and physicochemical 
properties include hardness and morphology. 
C) To observe the effect of drug loading on the morphology of the PCL matrix using 
scanning electron microscopy and differential scanning calorimetry. 
D) To investigate the in vitro release behaviour of antimicrobials from PCL matrices. 
E) To determine the level of antibacterial activity of drug released from the PCL 
matrices. 
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EVALUATION OF POLYCAPROLACTONE MATRICES 
FOR THE DELIVERY OF METRONIDAZOLE IN THE 
INTRAVAGINAL TREATMENT OF BACTERIAL 
VAGINOSIS 
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1. Abstract 
Microporous, poly (ɛ-caprolactone) (PCL) matrices loaded with the antibacterial 
metronidazole were produced by rapidly cooling suspensions of drug powder in PCL 
solutions in acetone. Drug incorporation efficiency of 40-53% was obtained on raising the 
drug loading from 5-20% w/w measured with respect to the PCL content. Rapid ‘burst 
release’  of 35 to 55% of the metronidazole content was recorded over 24h when matrices 
were immersed in simulated vaginal fluid (SVF), due to the presence of large amounts of 
drug on matrix surface as revealed by RAMAN microscopy. Gradual release of around 
80% of the drug content occurred over the following 12 days. Metronidazole released from 
PCL matrices in SVF retained antimicrobial activity against Gardnerella vaginalis in vitro at 
levels up to 97% compared to the free drug. On the basis of these results, the 15% w/w 
metronidazole loading was selected to check the effect of polyethylene glycol (PEG) on 
drug loading, release and mechanical properties of PCL. Incorporation efficiency of 
metronidazole increased from 54% to 91% as the concentration of PEG increased from 
0% to 10% w/w with respect to PCL. Release of metronidazole within 24 hours of 
immersion in simulated vaginal fluid at 37°C increased from 48 to 76% as PEG loading 
increased from 0% to 10% w/w, and overall release within the 12 day experimental period 
was greater for 10% PEG (95% drug release) in comparison to 0% PEG (76% released). 
Released metronidazole retained a high relative antibacterial activity of 88-97% and there 
was no discernible effect of PEG on the antimicrobial activity of metronidazole according to 
a disc diffusion assay against G. vaginalis. Basic modelling predicted that the 
concentrations of metronidazole released into vaginal fluid in vivo from the approximate 
quantity of PCL matrix that would be used in an intravaginal ring (IVR) would exceed the 
minimum inhibitory concentration (MIC) of metronidazole against G. vaginalis.  
2. Introduction  
Bacterial vaginosis (BV) is one of the most common genital conditions occurring in women 
of child bearing age1 and is caused by the displacement of normal vaginal lactobacilli by 
other species notably Gardnerella vaginalis, Mycoplasma homonis and anaerobic bacteria 
such as peptostretococci, Prevotella spp. and Mobiluncus spp2. BV is associated with a 
range of health problems such as altered vaginal discharge and odour. It is also related 
with the adverse pregnancy outcomes including post-partum, post-abortion, and post-
hysterectomy infections. BV increases women’s risk of acquiring pelvic inflammatory 
disease and potentially some sexually transmitted infections (STIs) such as Chlamydia 
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trachomatis, Neisseria gonorrheae and HIV by inducing changes in the mucosal immune 
environment of the vagina2,3,4. BV is estimated to have a mean prevalence of 14% when 
considering both developed and developing countries, but as the microflora of the vaginal 
ecosystem changes throughout the menstrual cycle, under the influence of exogenous 
hormones and during reproductive life in most women it is difficult to estimate the true 
prevalence or impact of BV5. In the United States, bacterial vaginosis affects 
approximately 80,000 pregnant women per year, resulting in an increased incidence of 
preterm delivery or low-birth weight. Treatment can reduce these risks and may in turn 
reduce the number of associated perinatal deaths and neurologic abnormalities in infants6.   
BV, when treated, is generally managed by using metronidazole, which belongs to the 
nitro-imidazole class of antibiotics and exhibits broad spectrum activity against most Gram-
negative and Gram-positive anaerobic bacteria7. Metronidazole is particularly attractive for 
the treatment of BV because it also eradicates any coexisting trichomoniasis, an STI 
caused by the protozoa, Trichomonas vaginalis3.  Metronidazole is generally administered 
orally in tablet form (2 g single dose or 400 mg, 12-hourly for 7 days) but this route is often 
associated with adverse gastrointestinal side effects, nausea, headache, anorexia and 
occasionally vomiting. The bitter or metallic taste of oral dosage forms presents a further 
disadvantage.  
The side effects of metronidazole have been avoided by vaginal administration. 
Unfortunately, solid vaginal formulations such as pessaries and tablets have a short 
residence time, necessitating frequent administration8. Semi-solid intravaginal gels 
incorporating metronidazole (0.75%) require daily administration of approximately 5 g gel 
for 5 days but are messy to apply, prone to leakage and concerns exist over effective 
coverage of the vaginal epithelium9. These factors have contributed to the recent upsurge 
of interest in intravaginal ring (IVR) devices for sustained delivery of antiviral agents10. 
IVRs offer advantages of low and continuous dosing over extended time periods, reduced 
side effects, self-administration and improved patient compliance. Conventional IVRs 
produced from silicone elastomer or poly (ethylene vinyl acetate) (pEVA) have been used 
clinically for many years for delivery of estrogen (hormone replacement therapy) and 
etonogestrel and ethinyl estradiol (contraceptive purposes)11. IVRs are being evaluated for 
sustained release of the non-nucleoside reverse transcriptase inhibitor, dapivirine as an 
anti-HIV microbicide and acyclovir for herpes prophylaxis12,13.  
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Conventional IVRs do however display a number of disadvantages for microbicide 
delivery; they are generally restricted to delivery of low molecular weight, hydrophobic 
drugs such as dapivirine. In addition, manufacture involves heating at 80°C for silicone 
elastomer or 140°C for pEVA which could degrade thermally-sensitive compounds. The 
synthetic polyester, poly (ɛ-caprolactone) (PCL) does not require such high temperatures 
as part of drug loading or shape moulding. PCL has been investigated extensively for 
many years for production of a range of drug delivery systems including microparticles, 
nanoparticles, films and fibres14. PCL nanoparticles loaded with the immunosuppressant 
cyclosporin, for example, have been reported to decrease the nephrotoxicity of the drug 
and efficiently target lymphocytes15. Microporous PCL matrices, prepared by precipitation 
casting16 or rapid cooling techniques17 are effective for sustained delivery of small 
hydrophobic drug molecules (progesterone)18, hydrophilic entities (gentamicin sulphate)16 
and macromolecules such as enzymes with retained activity19. Recently, the potential 
utility of PCL in vaginal delivery was demonstrated for the antibacterial, ciprofloxacin, with 
loadings of 7.3-15% w/w, and the antifungal, miconazole (loadings of 1-3% w/w). Drug 
released into simulated vaginal fluid retained high antibacterial activity against N. 
gonorrhoeae and C. albicans, respectively20.  
In the present study the loading and release of metronidazole from PCL matrices is 
investigated. The potential to adjust metronidazole loading, release and mechanical 
properties of PCL with the addition of polyethylene glycol (PEG) is also considered. PEG is 
amongst the most commonly used water soluble pore forming agents (or porogens) that is 
incorporated into drug delivery systems to enhance the rate of drug release21-23 and is safe 
for vaginal delivery28. The presence of PEG increases pore formation by solubilisation and 
extraction of the PEG phase and thus is expected to facilitate fluid uptake, improving the 
loading, dissolution and release of co-incorporated drugs24-27.   
3. Materials and methods 
3.1 Materials 
PCL (Mw 115,000 Da, CAPA 6500) was obtained from Solvay Interox, Warrington, UK. 
Metronidazole, polyethylene glycol (MW 1500), glucose, urea, bovine serum albumin, 
potassium hydroxide, calcium chloride, glycerol, lactic acid and acetic acid were 
purchased from Sigma-Aldrich, Australia. G. vaginalis stock culture in glycerol broth was 
supplied by Micromon, Monash University, Clayton, VIC, Australia. Horse blood agar, 
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heart infusion broth (HIB), CO2 generation kit and antimicrobial susceptibility blank discs 
were obtained from Oxoid, Basingstoke, UK.  
3.2 Production of metronidazole-loaded PCL matrices 
PCL solutions of concentration 15% w/v were prepared by dissolving the polymer in 
acetone at 50°C. Metronidazole was ground to a fine powder and added to the PCL 
solution to produce suspensions of concentrations 5, 10, 15 and 20% w/w of the PCL 
content. The resulting suspension was homogenized for 30s at 5000 rpm using a Silverson 
SL27 homogenizer (Silverson Machines, Chesham, Bucks, UK). The suspension was 
poured into a polypropylene syringe body (3 mL) which was used as a mould and cooled 
in ethanol at -80°C for 2 h to allow crystallization of PCL. The hardened matrices were 
removed from the moulds and immersed in 10 mL ethanol for 24 h to extract acetone by 
solvent exchange. Samples were removed from ethanol and left to dry under ambient 
conditions to evaporate residual solvents. The final matrices were in the form of cylinders 
of diameter 6.5 ± 0.5 mm and length 45.0 ± 5 mm. 
PEG was additionally incorporated into the PCL matrices in the same way. 15% w/v PCL 
matrices loaded with combination of metronidazole (15% w/w) and PEG (0, 2, 3, 4, 5 and 
10% w/w) were prepared. The final PCL/PEG matrices were in the form of cylinders of 
diameter 6.5 ± 0.2 mm, length 45.0 ± 7 mm and weigh (410 ± 15 for PCL) (415 ± 16 for 
PCL/PEG) matrices.  
3.3 Determination of metronidazole content 
Samples of PCL and PCL/PEG matrices loaded with metronidazole were weighed and 
dissolved in 2 mL of dichloromethane (DCM). Precipitation of PCL was induced by adding 
5 mL of 30% methanol followed by shaking at 1000 rpm overnight (Vibrax VXR, IKA, 
Werke Staufen, Germany) to evaporate DCM and obtain partitioning of the drug into the 
methanol phase. The concentration of metronidazole in methanol was measured by using 
UV spectrophotometry (Varian, Cary 50 Bio, Agilent Technology, USA) at an absorbance 
wavelength of 319 nm and calculated using a calibration curve  of metronidazole in 30% 
methanol (4-20 µg/mL). Experiments were performed in triplicate to obtain values of actual 
drug loading and loading efficiency. 
 
 
33 
 
3.4 Morphology 
The morphology of the surface and interior of drug-free and drug-loaded PCL and 
PCL/PEG matrices was examined using a JSM 6460LA scanning electron microscope 
(SEM, JEOL, Japan). Specimens were mounted on aluminium SEM stubs using carbon 
tabs and sputter coated with platinum using an Eiko-Sputter coater automatic mounting 
press, prior to examination at a voltage of 5 kV. 
3.5 Thermal properties  
The thermal characteristics of matrices were investigated using differential scanning 
calorimetry (DSC) (DSC 1 STARe System, Mettler Toledo, Switzerland) under a nitrogen 
atmosphere. Samples of matrices were weighed, placed in sealed aluminium pans and 
heated over the temperature range -100°C to 150°C at a rate of 10°C/min. The peak 
melting point, glass transition temperature (Tg) and heat of fusion data were obtained 
using the DSC software facility. Crystallinity (%) was estimated using a value of 139.5 J/g 
for the heat of fusion of fully crystalline PCL18.  
3.6 Shore hardness testing  
Shore hardness testing was carried out using a CT3 Texture Analyzer (Brookfield 
Engineering Laboratories Inc., Middleboro, MA, USA). As-moulded cylinders were 
mounted horizontally and compressed locally at a speed of 0.1 mm/min to a depth of 2.0 
mm using a 2 mm diameter, flat-ended, cylindrical probe (TA39). The hardness (or 
indentation resistance) of each sample was calculated from the applied force measured at 
a depth of 2 mm. A pEVA IVR (Nuvaring®, Schering-Plough Pty limited, NSW, Australia) 
was subjected to the same test procedure for comparison. 
3.7 In vitro release of metronidazole 
Cylindrical sections of metronidazole-loaded matrices (length 45 mm) were subjected to a 
release study in simulated vaginal fluid. Prior to testing, both ends of each sample were 
sealed by dipping in 5% w/v solution of PCL in acetone followed by drying in air. 
Experiments were performed in triplicate. Each sample was placed separately in 10 mL of 
SVF and retained at 37°C in an incubator. SVF was prepared according to the method of 
Owen and Katz29 and contained 3.51 g NaCl, 1.40 g KOH, 0.222 g Ca(OH)2, 0.018 g 
bovine serum albumin, 2.00 g lactic acid, 1.00 g acetic acid, 0.16 g glycerol, 0.4g urea and 
5.0 g glucose up to 2 L of  distilled water. The pH was adjusted to 4.2 using 10% HCl. The 
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release media were collected and replaced with fresh media daily for 12 days. The 
concentration of drug in the release medium was analysed by UV spectrophotometry 
(Varian, Cary 50 Bio, Agilent technology, USA) at 319 nm by comparison with a standard 
curve produced using a series dilution of metronidazole in SVF.  Separate release 
samples were stored at 4°C for antimicrobial testing.  
3.8 Analysis of drug distribution  
Raman spectroscopy was used to map 10% w/w metronidazole-loaded PCL matrices to 
characterise the drug distribution for correlation with drug release behaviour. A 1 mm thick 
disk was taken from the middle of drug-loaded PCL matrices, placed on a glass slide and 
scanned using a Raman microscope (Nicolet Almega XR Dispersive Raman, 
Thermoscientific, USA) along the radius or around the circumference at spatial intervals of 
100 µm. 
3.9 In vitro assay of antimicrobial activity 
The antimicrobial activity of metronidazole released from the matrices was assayed with 
G. vaginalis using the disc diffusion method. G. vaginalis was stored as stock cultures in 
40% glycerol at -80°C. G. vaginalis was grown for 48 h at 37°C on horse blood agar plates 
and the colonies of bacteria were then scraped from the agar surface using a speader and 
heart infusion (HI) broth. The cell suspension was then diluted in HI broth and plated onto 
horse blood agar plate to get approximately 100 CFU per plate. A blank disc (Oxoid) was 
placed at the centre of each inoculated plate and 100 µL of drug standard solution in SVF 
or release medium containing metronidazole was added to the disc. The plates were 
incubated at 37°C for 48 h under anaerobic conditions and the diameter of the zone of 
inhibition surrounding the disc was measured. The relative antibacterial activity of 
metronidazole released from PCL matrices was calculated by comparison with the zone of 
inhibition obtained using non-formulated drug solutions of metronidazole of the same 
concentration. SVF and release media used for incubation of blank PCL and PEG/PCL 
matrices were used as controls. 
3.10 Statistical analysis 
Significant differences between samples in their drug loading, drug release on day 1 and 
day 14, glass transition temperature, crystallinity and shore hardness were tested using 
one-way ANOVA with a Tukey multiple comparisons test (p<0.05).  
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4. Results and Discussion 
4.1 Morphology of matrices 
Metronidazole-loaded PCL matrices prepared by rapidly cooling suspensions of drug 
powder in PCL solution exhibit flexibility, uniformity of structure and an absence of large 
cracks and voids in the sample surface and interior. SEM examination of drug-free PCL 
matrices revealed a nodular type of morphology and irregular shaped pores with 
dimensions of 2-4 µm (Figure 1a). The surface of metronidazole-loaded matrices exhibited 
a flat texture (Figure 1b), probably resulting from contact of the matrix with the mould wall. 
Fine fissures were observed in certain areas along with evidence of trapezoidal-shaped 
drug crystals 1-2 µm in size. The internal structure of metronidazole-loaded PCL matrices 
exhibited a woven, lamellar type of morphology (Figure 1c) and the characteristic 
microporous PCL phase consisting of 2-5 μm pores. Trapezoidal drug crystals are visible 
at higher magnification (Figure 1d, arrowed). The addition of PEG into matrices was 
associated with larger pore sizes (Figure 1e).   
4.2 Metronidazole loading 
Actual loading of metronidazole in PCL matrices was lower than the corresponding 
theoretical loading (Table 1), with approximately 50% of the quantity added to the mixture 
being incorporated. This is explained by the relative solubility of metronidazole in the 
solvent used to extract acetone from the hardened PCL matrices, required to avoid 
shrinkage and cracking of the PCL matrix following crystallization and drying, which results 
in partitioning of metronidazole and elution from the matrix. The solubility of metronidazole 
in methanol, acetone and ethanol is 32.2, 20.7 and 5.0 mg/ml30, respectively. Methanol 
was also found to be an issue for preparation of ciprofloxacin- and miconazole-loaded PCL 
matrices, leading to 73% and 20% loading efficiency, respectively20. Ethanol instead of 
methanol for acetone extraction resulted in an increase in catalase loading in PCL 
matrices19 due to the lower solubility of the enzyme in ethanol, so ethanol was used for this 
stage instead of methanol in the present study in order to reduce drug loss.  
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Figure 1: Morphology of drug-free and metronidazole (MTZ)-loaded PCL matrices. A) 
Interior of drug-free PCL matrix B) Surface of 5.4% MTZ-loaded PCL matrix C) 
Interior of 5.4% MTZ-loaded PCL matrix D) Interior of 5.4% MTZ-loaded PCL matrix 
showing presence of drug crystals (arrowed) E) Surface of PCL matrix loaded with 
13.7% w/w metronidazole and 10% PEG. 
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Table 1: Actual loading, loading efficiency and shore hardness of metronidazole in 
PCL matrices prepared using the rapid cooling technique. Within each column, 
numbers sharing the same superscript letter are not significantly different (P<0.05).  
Theoretical drug 
loading 
 Actual loading 
(%w/w) 
Incorporation 
efficiency  
Shore hardness 
(mN/mm2) 
0     0      0 3986 ± 210a 
5 2.0 ± 0.5a 40 ± 10.1a 3841 ± 190a   
10 5.4 ± 0.8b 54 ± 8.0ab 1522 ± 75b 
15 8.1 ± 0.8c 54 ± 5.3ab 1268 ± 62b 
20 10.6 ± 0.7d 53 ± 3.5b  888 ± 32c 
In the absence of PEG, loading efficiency of 54% was obtained for the theoretical loading 
of 15% metronidazole, i.e. only 8.1% loading was achieved (Table 1). Drug loading and 
loading efficiency improved with increasing PEG loading (Table 2), reaching 13.7% w/w 
metronidazole loading (91% loading efficiency) when 10% PEG was added. This result is 
consistent with expectations, as this effect of PEG has been measured previously; for 
example, loading efficiency of nevirapine increased from 22 to 44% on addition of 8% w/v 
of PEG as a solid dispersion with the drug to PCL matrices17. The reduction in loss of 
metronidazole with increasing PEG content of the matrix suggests that the PEG phase 
shields the drug from exposure to ethanol, possibly by forming a viscous solution on 
dissolution that impedes access of the solvent to the drug particles. PEG may also have 
dissolved in the ethanol, and so it is likely that there was some loss of PEG during the 
production. The values given for PEG loading (Table 2) indicate the quantity added, but 
the actual loading of PEG was not measured in this study. 
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Table 2: Actual loading, incorporation efficiency and shore hardness of 
metronidazole (MTZ) in PCL/PEG matrices. 15% w/w metronidazole was added to 
PCL solution in acetone with the PEG concentration indicated, and the actual 
quantity of metronidazole loaded was measured using UV spectrophotometry at 319 
nm. Within each column, numbers sharing the same superscript letter are not 
significantly different (P<0.05). 
4.3 Thermal properties  
DSC analysis revealed more than doubling of the crystalline content of PCL matrices from 
around 33% to 76% with increasing metronidazole loading of the material from 0 to 8.1% 
w/w (Table 3).  Previous studies by Chang et al. revealed crystallinity levels of 50-75% for 
drug-free PCL matrices and both increases and decreases in PCL crystallinity depending 
on the type of drug molecule incorporated in the matrix18. Progesterone inclusion (10%) 
resulted in a major reduction of crystallinity of around 12% from 66% to 54%18, whereas 
gentamicin sulphate particulates increased the crystallinity of PCL matrices by 4-8%. 
Progesterone particulates were considered to inhibit PCL crystal nucleation and growth, 
while gentamicin sulphate particles acted as nucleating agents to enhance PCL 
crystallisation. The significant increase in crystallinity of the PCL phase with metronidazole 
loading measured in the present study indicates the strong effect of the dispersed drug 
particles on nucleation and crystal growth of PCL. The particles of metronidazole appear to 
promote heterogeneous or epitaxial crystallisation of PCL, which is known to be influenced 
PEG loading 
(% w/w) 
Actual MTZ loading 
(% w/w) 
MTZ 
Incorporation 
efficiency  
Shore hardness 
(mN/mm2) 
0 
2 
8.1 ± 0.8a 
8.9 ± 0.7ab 
   54.0 ± 5.3a 
   59.3 ± 4.7ab 
1420 ± 135a 
1322 ± 205a 
3 9.9 ± 0.8bc     66.0 ± 5.3bc 1273 ± 165a 
4 10.8 ± 0.5c    72.0 ± 3.3c 1155 ± 163a 
5 12.5 ± 0.3d    83.3 ± 2.0d 1085 ± 98a 
10 13.7 ± 0.3d    91.3 ± 2.0d  653± 77b 
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by similarities in the crystal lattice of the substrate and crystallising polymer and also by 
the surface topography of the substrate (defects, steps and terraces)31. The lower 
crystallinity of the drug-free PCL phase in the present study compared with samples 
produced by Chang et al.18 reflects rapid cooling of the PCL solution compared with room 
temperature precipitation technique. Rapid cooling restricts polymer chain mobility and 
crystal growth. The glass transition temperature indicates the reversible change in the 
amorphous regions of a polymer from a hard and relatively brittle condition to a viscous or 
rubbery state. The increase in Tg found with increasing metronidazole loading (Table 3) 
indicates an interference or restriction of PCL chain mobility due to the presence of the 
dispersed drug particles in the matrix.  
Table 3: Thermal analysis of metronidazole-loaded PCL matrices. Within each 
column, numbers sharing the same superscript letter are not significantly different 
(P<0.05).  
Theoretical drug 
loading (%w/w) 
Actual Drug 
loading (%w/w) 
Crystallinity 
(%) 
Glass transition    
temperature (Tg) 
(°C) 
0 0    33.4 ± 2.3a -60.1 ± 0.6a 
5 2.9    42.4 ± 1.9b -58.1 ± 0.4b 
10 5.4    56.1 ± 2.2c -56.5 ± 0.4c 
15 8.1    74.8 ± 1.6d -55.6 ± 0.5cd 
20 10.6    75.6 ± 1.2d -54.5 ± 0.6d 
Thermograms of pure PEG 1500, pure metronidazole and pure PCL matrix show a melting 
peak at around 52°C, 162°C and 62°C respectively (Figure 2a-c). DSC thermograms of 
PCL/PEG matrices having a low 3% PEG and containing 9.9% w/w metronidazole loading 
revealed a main endothermic peak around 67°C with a shoulder at approximately 62°C 
(Figure 2d) representing melting of the PCL/PEG and PCL mixed phases of the matrix 
respectively. A higher PEG loading of 10% showed dominance of the PEG melting peak at 
58°C with a second melting peak at 62°C corresponding to PCL (Figure 2d) which 
suggests that PCL and PEG exist in two different phases at higher PEG concentration. 
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Similar separation of peaks in the DSC thermograph for PEG and the polymer phase was 
reported previously for PEG-modified polylactic acid films32 and etanidazole-loaded 
PLGA/PDLA microspheres33.  
4.4 Shore hardness 
The shore hardness values determined by texture analysis for metronidazole-loaded PCL 
matrices are shown in Table 1. Matrices containing low drug loadings (2% w/w) exhibited 
similar hardness to unloaded samples (3900 mN/mm2). Matrix hardness decreased to 
around 900 mN/mm2 when the drug loading was increased to 10.6% metronidazole, 
indicating that excessive drug loading causes deterioration and weakening of the matrix 
structure, probably by micro-cracking effects which are also influential in relation to drug 
release behaviour34. The hardness of  the poly(ethylene vinyl acetate) IVR (Nuvaring®) 
was found to be 9280 mN/mm2 which is almost 2.5 times more than the 2% 
metronidazole-loaded PCL samples. Thus microporous PCL IVRs potentially offer scope 
for improving user comfort compared with conventional materials. This requires careful 
consideration when optimising the properties of intravaginal ring devices based on 
metronidazole-loaded PCL matrices since adequate mechanical properties are required to 
withstand the flexural loads experienced during insertion and during device residence in 
the vagina and thus ensure successful clinical performance.  
Hardness of the matrices was reduced even further with the addition of PEG. Hardness 
reduced by more than 50% from 1420 mN/mm2 to 653 mN/mm2 when PEG was 
incorporated at a level of 10% in PCL matrices (Table 2). Increasing the loading of PEG 
was observed to cause the matrices to be more brittle in nature. This may be explained by 
PEG interfering with the internal structure of PCL and leading to weakening of the PCL 
structure. The morphology of PLGA/PDLA polymer microspheres changed even on the 
addition of only 1% PEG, which was hypothesised to be due to the fact that PEG 
interacted with the PLGA/PDLA polymer and increased its chain mobility, thereby 
weakening the polymeric structure33. 
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Figure 2: DSC thermogram of A) pure PEG 1500, B) pure metronidazole, C) drug-free 
PCL matrix, D) 3% PEG with 9.9% w/w metronidazole and E) 10% PEG with 13.7% 
w/w metronidazole  
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4.5 In vitro release of metronidazole from PCL matrices 
Drug release from PCL matrices featuring dispersed drug particles is governed by a 
number of factors including drug loading, uptake of release medium and drug solubility in 
the fluid phase, matrix porosity and the rate of drug diffusion in fluid-filled pores of the 
material. Since PCL exhibits a bioresorption time in excess of two years, the detailed pore 
structure (pore size, connectivity and tortuosity) can exert a major influence on drug 
transport from the matrix.  
There was a large burst release, measured as the drug concentration in the simulated 
vaginal fluid after 1 day of immersion of each PCL cylinder (Figures 3 and 4). The 
magnitude of the burst release increased with drug loading of the matrix from 35% for 
2.0% loaded matrices to almost 60% for the most highly loaded PCL matrix (10.6%), with a 
linear relationship between day 1 release and drug loading (Figure 5; R2=0.9904). This 
burst release suggests the presence of large amounts of drug particles at or close to the 
matrix surface and is supported by the SEM observations described above (Figure 1b). 
Gradual drug release occurred from day 2 onwards, giving rise to an almost linear profile 
over the following 12 days that showed little difference between drug loadings, suggesting 
that drug loading within the core of the PCL was similar for all drug loadings used. In the 
case of low drug loading, gradual release of metronidazole is expected to occur 
predominantly through interconnected pores and channels inherent in the microporous 
PCL matrix since the separation of drug particles will not favour formation of 
interconnected macropores by dissolution of contacting drug particles. Increasing numbers 
of interconnected macropores, fissures and channels are expected in the highly loaded 
systems, due to contact of drug particles and micro-cracking effects34, which facilitate entry 
of release medium and enhance drug dissolution and extraction. Around 75% of the drug 
load was released from all samples by day 13, with no significant difference associated 
with drug loading, demonstrating in general high pore interconnectivity and thus delivery 
efficiency. Standard deviation around each mean was reasonably large (Figure 3), which 
might be due to the sedimentation of the drug during production leading to unequal 
distribution of drug within the matrices. 
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Figure 3: Cumulative (%, mean ± sd of 3 replicates) release of metronidazole (MTZ) 
from PCL matrices containing 2, 5.4, 8.07 and 10.6% MTZ in simulated vaginal fluid 
at 37°C 
 
 
 
Figure 4: Daily release of metronidazole (MTZ) release (µg) from PCL matrices in 
simulated vaginal fluid at 37°C (mean of 3 replicates) 
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Figure 5: Amount of metronidazole release (%) on day 1 of immersion of PCL 
matrices in simulated vaginal fluid at 37°C (mean ± sd of 3 replicates) plotted 
against the metronidazole loading (%) within each of the PCL matrices. Linear 
regression is shown for PCL matrices (y = 2.36x + 28.59; R2 = 0.9904), and for PCL-
PEG matrices excluding the highest metronidazole loading (y = 2.01x + 28.44; R2 = 
0.9857). For the points on each line analysed separately, points with the same 
lowercase letter shown above (PCL matrices) or below (PCL-PEG matrices) are not 
significantly different. 
The daily drug release profile (Figure 4) is important because it helps to predict that the 
amount of drug release is sufficient against the microorganism responsible for the disease 
during the whole release period. The minimum amount of metronidazole released in a 
single day was 51 µg measured at day 10 for the 5.4% metronidazole-loaded matrices. 
Incorporating PEG into PCL matrices at levels up to 5% was also characterised by a 
prominent burst effect at day 1 resulting in rapid loss of 45-55% of the metronidazole 
content (Figure 6). There was a linear relationship between day 1 release and drug loading 
for matrices prepared using 0 to 5% PEG (Figure 5; R2=0.9857) but the day 1 burst effect 
was significantly higher and did not follow the same linear relationship once the 
concentration of PEG added to the mixture increased to 10%. Excluding this point, at day 
1 the concentration of metronidazole released from matrices that incorporated PEG were 
very similar to those without PEG for equivalent drug loadings (Figure 5) suggesting that 
PEG had no effect at this early stage of release. In contrast, PCL matrices prepared with 
10% PEG may have experienced rapid dissolution of the hydrophilic PEG phase which 
facilitated drug release from the matrix interior.  
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The cumulative amount of metronidazole released from PCL-PEG matrices increased 
gradually over the subsequent 11 days to reach 70-85% for PCL matrices containing up to 
5% PEG and 12.5% metronidazole. This behaviour may be attributed to development of 
an interconnected pores and channels structure following PEG dissolution and extraction 
within the inherently microporous PCL phase, which facilitates metronidazole transport 
from the matrix core. Notably, incorporating 10% PEG resulted in release exceeding 90% 
by day 2 and quickly reaching 95% (Figure 6), indicating rapid production of an extensive 
interconnected pore network that facilitates ingress of medium, drug dissolution and 
transport from the matrix. This data indicates that drug release suitable for the 7 day 
duration of therapy required for metronidazole may be possible by further adjusting the 
amount of PEG blended with PCL. Similar increase in drug release was noticed on 
addition of PEG in bi/tri-layered PCL films loaded with a combination of paclitaxel and 5-
fluorouracil accelerated paclitaxel release from 60 to 90% within 100 days in PBS when 
10% PEG was incorporated35. Similarly, 5-fluorouracil release from PCL films was 
complete within 22 h for films containing 40% drug with 5% PEG, but within only 12 h for 
films incorporating 40% drug and 15% PEG36. The minimum release measured was 61 
µg/mL on day 11 for matrices prepared with 4% PEG and containing 10.8% metronidazole 
(Figure 7) except for the matrices loaded with 13.7% metronidazole and 10% PEG where 
all the drug released within 5 days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Cumulative release (% of total incorporated) of metronidazole (MTZ) in 
simulated vaginal fluid at 37°C from PCL matrices containing 0 to 10% PEG 
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Figure 7: Daily release of metronidazole (MTZ) release (µg per day) in simulated 
vaginal fluid at 37°C from PCL matrices containing 0 to 10% PEG    
4.6 Drug distribution  
The Raman spectra of PCL showed a characteristic peak in the region of 3000 cm-1 due to 
C-H stretching; small peaks at around 1800-1700 cm-1 are assigned to C=O stretching, 
while the peak at 1500 cm-1 is attributed to δCH2 and that at 1200-1280 cm-1 is due to 
ΩCH237. The spectra of PCL matrices revealed an absence of those molecules 
characteristic of the solvents used (acetone, ethanol) in matrix preparation.  
Raman peaks for metronidazole at 1500-1650 cm-1 are due to C=N stretching. In‐plane 
and out‐of-plane deformation vibrations are normally observed as sharp but weak to 
medium intensity bands in the region 1300‐750 cm-1. Small peaks around 800 cm-1 are 
due to NO2 group scissoring, wagging, rocking and twisting38. 
The Raman spectra in Figure 8 were generated at radial positions starting from the centre 
of a 5.4% metronidazole-loaded PCL matrix disk and moving toward the edge. The distinct 
peaks in the region of 3000 cm-1 and 1000-1500 cm-1 are due to the presence of the 
polymer and drug respectively. The traces clearly indicate the change in peak intensity 
corresponding to differences in drug concentration at different positions within the sample, 
which reflects the dispersion of drug powder within the PCL matrix. The high intensity 
Raman spectra obtained at points near the sample edge for the 5.4% metronidazole-
loaded PCL matrix (Figure 8) are indicated by the arrow. The high concentration of the 
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metronidazole was further confirmed by running the RAMAN along the edges (Figure 9). 
The high intensity peaks represent the presence of high concentration of metronidazole, 
which support the SEM images of drug crystals located at the sample surface and explain 
the high burst release behaviour of metronidazole at day 1 of release testing (Figure 4).  
 
Figure 8: Raman spectra obtained at different radial positions in a transverse 
section of 5.4% w/w metronidazole-loaded PCL matrix with the spectra displaced on 
the y-axis to allow the data to be visualised. The arrow indicates high intensity 
peaks obtained at points close to the edge of the PCL matrix. 
 
 
Figure 9: Raman spectra obtained at different edge points in a transverse section of 
5.4% metronidazole-loaded PCL matrix, with the spectra displaced on the y-axis to 
allow the data to be visualised. 
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4.7 Antibacterial testing 
G. vaginalis is an anaerobic, β-haemolytic, oxidase-negative, catalase-negative, gram 
variable bacterium, which is detected in all women diagnosed with BV and plays an 
important role in its pathogenesis5. The antibacterial activity of non-formulated 
metronidazole and drug released from PCL matrices into SVF against G. vaginalis was 
investigated using a disc diffusion assay to determine the effect of matrix formulation and 
matrix residence time in SVF on drug activity and to assess any implications for in vivo 
performance and dosing regimens. A zone of inhibition increasing from 7 to 20 mm 
diameter was observed for control drug solutions in SVF with increasing concentration 
from 25-125 µg/ml (Figure 10). No zone of inhibition was observed in the case of control 
samples comprising SVF alone or release media obtained from drug-free PCL matrices. A 
linear relationship was observed between metronidazole concentration and the diameter of 
the zone of inhibition, with a high correlation coefficient (R2 = 0.962) for the standard.  
 
Figure 10: Relationship between concentration of metronidazole and diameter of 
zone of inhibition against G. vaginalis for non-formulated metronidazole (standard) 
and drug released from PCL matrices into SVF (sample)  
The relative antibacterial activity (%) of metronidazole released from 5.4% drug-loaded 
PCL matrices into SVF was obtained by comparing the diameter of the zone of inhibition 
obtained for standard metronidazole solution and metronidazole-containing release media 
at equivalent drug concentrations. A high relative antibacterial activity (88-97%) was 
exhibited by released drug over a 10 day release period (Figure 11). No significant 
difference in activity was noticed, indicating that the drug is stable during the study period. 
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The slightly lower activity in comparison to pure drug might be due to prolonged exposure 
of the drug within the PCL matrix to elevated temperature (37°C for up to 10 days) and the 
fairly complex biochemical environment presented by the SVF. 
 
 
 
 
 
 
 
Figure 11: Relative activity (%) of metronidazole released from 5.4% drug-loaded 
PCL matrices in simulated vaginal fluid at 37°C over 10 days 
A similar relative antibacterial activity of 86-96% was measured for metronidazole released 
from the PCL/PEG matrices compared with metronidazole solutions in SVF of equivalent 
concentration, indicating that PEG has no effect on the antibacterial property of the drug. 
The minimum daily amount of metronidazole released into 10 mL SVF from PCL matrices 
was 51 µg at day 10 from a 5.4%-drug loaded matrix (Figure 4). For matrices that also 
incorporated PEG, the minimum was 61 µg/mL on day 11 for 4% PEG and containing 
10.8% metronidazole; this excludes the matrices containing 10% PEG and 13.7% 
metronidazole which had complete release within 5 days (Figure 6). If an IVR of linear 
length 150 mm (outer diameter 58 mm, inner diameter 38 mm) and weight (1.5 g) were 
produced, it would be approximately 3.5 times that of the matrices studied herein (45 mm, 
0.4 g). Therefore the minimum release amount of 5.1 µg/mL/day corresponds to a drug 
release rate from a PCL IVR of around 18 μg/mL/day. Indeed, in a concurrent PhD project, 
nevirapine and tenofovir release from PCL matrices and PCL IVRs was directly 
proportional to PCL length40. The predicted concentrations of drug which would be 
released from a PCL IVR into vaginal fluid are above the minimum inhibitory concentration 
(MIC) against G. vaginalis (2-12.8 µg/mL)39 during the study period. This is based on the 
assumption that the in vitro release rate from PCL matrices is similar to the in vivo release 
rate from a PCL vaginal ring and a maximum vaginal fluid turnover rate of 8 mL/day 
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applies. These estimates do not take into account the complex variations in vaginal fluid 
volume and biochemical composition over time, or the possibility of systemic uptake of 
drug.  
5. Conclusion 
Metronidazole antibacterial activity was retained after loading and releasing from PCL 
matrices. The amount of drug released into SVF on each day of the 14 day study was 
calculated to be more than the MIC of the bacteria causing bacterial vaginosis.  
Loading efficiency was only a maximum of 54%. Addition of PEG into the mixture during 
matrix formation raised incorporation efficiency considerably, for example addition of 10% 
PEG was associated with 91% of the metronidazole being incorporated. Unfortunately 
around 95% of drug came out within 5 days but a small reduction in PEG concentration 
would be expected to provide a maximum release over a 7 day period, which is currently 
the duration of therapy used. The daily drug release from all the matrices studied, loaded 
with 0 – 5% of PEG and 8.1–12.5% metronidazole, was more than the MIC against an 
organism which is major cause for bacterial vaginosis, G. vaginalis.  
As PCL matrices show some potential for the intravaginal delivery of antibacterial agents 
that treat STIs, the next step must be to determine whether they are safe for vaginal use. 
Additionally, although PEG improved drug loading, it also lead to the deterioration of 
mechanical properties of the polymer so subsequent research should focus on improving 
drug loading by modification of the method but without the addition of PEG. 
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CHAPTER 3  
INVESTIGATION OF POLYCAPROLACTONE MATRICES 
FOR THE INTRAVAGINAL DELIVERY OF DOXYCYCLINE 
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1. Abstract 
Poly(ɛ-caprolactone) (PCL) matrices loaded with doxycycline were produced by rapidly 
cooling suspensions of the drug powder in PCL solution in acetone. Drug loadings of 5, 10 
and 15% w/w of the PCL content were achieved. Exposure of doxycycline powder to 
matrix processing conditions in the absence of PCL revealed an endothermic peak at 65°C 
with the main peak at 167°C, suggesting solvatomorph formation. Rapid ‘burst release’ of 
24% to 32% was measured within 24 h when matrices were immersed in simulated vaginal 
fluid (SVF) at 37°C, due to the presence of drug at or close to the matrix surface; which is 
further confirmed by scanning electron microscopy. Gradual release of 66-76% of the drug 
content occurred over the following 14 days. SVF containing doxycycline released from 
drug-loaded PCL matrices retained 81-90% antimicrobial activity compared to the non-
formulated drug. The concentrations of doxycycline predicted to be released into vaginal 
fluid from a PCL matrix in the form of an intra-vaginal ring (IVR) would be sufficient to 
kill N. gonorrhoea and many other pathogens. These results indicate that PCL may be a 
suitable polymer for controlled intra-vaginal delivery of doxycycline for the treatment of 
STIs. ). No significant reduction in cell viability was recorded when leachates prepared by 
incubating PCL matrices in SVF for 28 days were tested against vaginal cell line 
(Vk2/E6E7) indicating PCL as a favourable polymer for production of vaginal delivery 
devices. 
2. Introduction 
Around 500 million cases of four of the major curable sexually transmitted infections 
(STIs), Chlamydia, gonorrhoea, syphilis and trichomoniasis, were recorded worldwide in 
2008, an increase of 11% from 20051, confirming the urgent need for improved prevention 
and treatment strategies. Doxycycline belongs to the tetracycline group of antibiotics and 
is highly effective against Gram-positive, Gram-negative, aerobic and anaerobic bacteria, 
Mycoplasma, Chlamydia trachomatis and some protozoa2. Thus, doxycycline is a 
commonly prescribed medication for the treatment of STIs. It exerts a bacteriostatic action 
by inhibiting bacterial ribosome function and therefore protein biosynthesis, while 
antiprotozoal activity results from inhibition of apicoplast ribosomal subunits leading to 
impaired fatty acid synthesis3. Doxycycline 100 mg given orally twice a day for 7 days is 
recommended by the Centre for Disease Control and Prevention for the treatment of 
genital Chlamydial infection4 and has been prescribed in combination with cephalosporin 
for the treatment of gonococcal infection5. Extended treatment, involving oral dosing (100 
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mg twice daily) for 14 days is recommended for the treatment of pelvic inflammatory 
disease6 and a dose of 100 mg twice daily for 21 days is first line treatment of 
lymphogranuloma venereum7. Doxycycline may also be prescribed as a second line of 
treatment for syphilis when patients are allergic to penicillin8.  
Doxycycline, being a lipophilic drug shows excellent tissue penetration and access to sites 
of infection in the female genital tract following oral administration and systemic 
distribution9. However, oral dosing can cause gastrointestinal side effects such as nausea, 
vomiting, diarrhoea, epigastric burning and esophageal ulcers10,11. In addition, the long 
duration of treatment may result in non-compliance issues, whereby patients do not 
complete the course of medication, resulting in an increased probability of treatment failure 
and drug resistance12.  
Vaginal formulations, including tablets, gels and creams, have been widely investigated as 
alternatives to oral dosage forms since they avoid first pass metabolism, gastrointestinal 
and wider systemic exposure to drug molecules which can produce severe side effects. In 
particular vaginal formulations of microbicides are receiving increasing attention for the 
treatment and prevention of STIs, especially HIV/AIDS. However, conventional semisolid 
formulations suffer major drawbacks of leakage and they are ‘messy’ to apply and there 
are concerns over inadequate coverage of the vaginal epithelium13. These disadvantages 
have been avoided by the development of intra-vaginal ring (IVR) devices which facilitate 
insertion and retention and allow long-term drug release in a predictable and controlled 
manner, thereby increasing patient acceptability14,15 and reducing compliance 
problems16,17.   
IVRs are conventionally manufactured from silicone elastomer, thermoplastic polyurethane 
and polyethylene vinyl acetate (pEVA). However, these polymers require high processing 
temperatures (silicone elastomer 80°C, pEVA 140°C) and doxycycline is prone to thermal 
degradation18-20. PCL could be a promising option for the delivery of doxycycline, due to 
the lower melting temperature of 60°C. PCL is synthetic polyester that has been studied 
extensively for controlled drug delivery and tissue engineering applications in a wide 
variety of forms including films, fibres, micro- and nanoparticles21. Microporous matrices of 
PCL have been investigated previously for vaginal delivery of the antivirals nevirapine and 
tenofovir22,23, the antibacterials gentamicin and metronidazole24,25, and the antifungal 
miconazole26, for prevention and treatment of STIs. The aim of this study was to explore 
the potential of PCL matrices for vaginal delivery of doxycycline through investigations of 
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the preparation, morphology, thermal and compressive properties and in vitro drug release 
of doxycycline from PCL matrices. In the previous study, the drug loading was very less 
which means the drug lost during production step. In the current study omission of drug 
step was tried to improve the drug loading to 100%.  
3. Materials and methods 
3.1 Materials 
Polycaprolactone (MW 115,000 Da, Capa 650) was obtained from Solvay Interox 
(Warrington, UK) and doxycycline hyclate from Alfa Aesar (Ward Hill, MA, USA). Sodium 
chloride, potassium hydroxide, calcium chloride, bovine serum albumin, glucose, glycerol, 
urea, lactic acid and acetic acid were purchased from Sigma Aldrich (Castle Hill, NSW, 
Australia). Solvents (acetone, acetonitrile) were of analytical grade. CO2 generating kit 
sachets were obtained from BD (New Jersey, USA). Thayer Martin agar, Lactobacilli MRS 
agar plates and anaerobic sachets were purchased from Micromedia (Melbourne, VIC, 
Australia). 
3.2 Preparation of doxycycline loaded PCL matrices 
A slight modification of a previously reported method25 was used to produce the matrices. 
A 15% w/v solution of polycaprolactone in acetone was produced by heating at 45°C for 45 
min. Doxycycline hyclate powder was added in concentrations of 5, 10 and 15% w/w of the 
PCL content, and the resulting suspension of drug in PCL solution was poured into 
polypropylene syringes (3 mL) and rapidly cooled at -80°C to produce a cylindrical 
polymeric matrix loaded with drug. After the cooling phase at -80°C for 24 h polymer 
matrices were removed from the syringes and dried for 24 h under ambient conditions to 
evaporate solvents. The resulting cylindrical matrices were loaded with 5% w/w, 10% w/w 
and 15% w/w doxycycline hyclate and had an average weight of 478 ± 6.3 mg, a diameter 
of 6.5 ± 0.5 mm and length 45.0 ± 5 mm. 
3.3 Morphology of drug loaded PCL matrices 
Scanning electron microscopy (SEM) (JEOL-6610LV SEM, Jeol Ltd., Tokyo, Japan) was 
performed on the drug-free and drug-loaded PCL matrices to investigate the internal and 
surface morphology. Samples for SEM were mounted on aluminium stubs using adhesive 
carbon tabs and sputter-coated with platinum using an Eiko sputter-coater prior to 
examination at 10 KV.  
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3.4 Thermal properties of doxycycline-loaded PCL matrices 
The effect of drug loading on the thermal characteristics of PCL was investigated using 
differential scanning calorimetry (DSC; DSC 1 STARe System, Mettler-Toledo, Ltd., 
Melbourne, VIC, Australia) under a nitrogen atmosphere. Samples of drug-free and 
doxycycline-loaded PCL matrices were cut, weighed and sealed in aluminium pans and 
subsequently heated from 30 to 330°C at 10°C/min. The crystallinity of the PCL phase was 
obtained using the DSC software (STARe) based on the heat of fusion value of 139.5 J/g 
for fully crystalline PCL polymer24.  
A DSC analysis was carried out of doxycycline powder that had been subjected to the 
same conditions used for matrix production but in the absence of PCL to investigate 
possible changes in drug crystallinity in the matrix caused by process conditions. This 
approach was adopted to compensate for the low weight of doxycycline in the PCL matrix 
samples which results in low enthalpy changes and therefore difficulties in obtaining 
information about drug crystallinity. Thus a weight of doxycycline powder corresponding to 
that used for matrix production was dispersed in acetone at 45°C and held at -80°C for 24h 
before drying under ambient conditions. Samples of treated and untreated doxycycline 
were analyzed by DSC as described above.   
3.5  Biocompatibility evaluation of PCL matrices  
PCL matrices of approximate weight 400 mg (accurately weighed) were immersed in 5 mL 
of sterile SVF in an incubator (Heidolph Inkubator 1000, Germany) at 37°C with shaking 
(120 cpm) for 4 weeks. Samples of SVF were collected at specific time points (1, 7, 14, 21 
and 28 days) and stored at -5°C until testing.  
3.5.1 Biocompatibility with vaginal epithelial cells 
The potential toxicity of extractables associated with production of PCL matrices was 
evaluated in vitro using the vaginal epithelial cell line (Vk2/E6E7). The cells were cultured 
in keratinocyte serum-free media supplemented with 0.1 ng/mL EGF, detached from the 
flask surface after 10 minutes. A 1:1 mixture of Dulbecco’s modified eagle’s media and 
Ham’s F12 media containing 10% fetal bovine serum (8 mL) was added to neutralize 
trypsin. The suspended cells were transferred into a centrifuge tube and spun down for 2 
minutes. The supernatant was discarded, the cells were resuspended in fresh serum-free 
growth media and 3 mL aliquots were transferred into fresh cell culture vessels. After 5 
passages, cells were seeded in 96-well plates (20,000 cells/well in 200 µL of growth 
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media) and incubated for 24 h. The growth media were subsequently replaced with the 
test and control samples and incubated for an additional 24 h. Prior to testing, the samples 
were filtered using 0.2 µm syringe filters under sterile conditions and diluted 1:6 with 
culture media (KSF supplemented with 0.1 ng/mL EGF, 50 µg/mL BPE, 1% v/v P/S, 0.4 
mM CaCl2). SVF diluted with nutrient media (1:6 dilutions) were used as no treatment 
control, SVF as toxic control and nutrient media used as positive controls, respectively. 
The percentage cell viability in each well following exposure to test samples (SVF which 
had contained PCL matrix) for 24 h was obtained by comparison with the no treatment 
control. MTS reagent (10 µL) was added to each well and the plate was incubated for 1 h 
at 37°C. The absorbance was measured at 490 nm using a Multi-Mode Microplate reader 
(iMARKTM, Bio-Rad laboratory Inc., USA) using 650 nm as the reference wavelength. Data 
were compared with the control (SVF diluted with culture media, 1:6) using one way 
ANOVA. 
3.5.2 Biocompatibility evaluation with a human vaginal isolate of Lactobacillus 
jensenii  
Lactobacilli are an important part of the vaginal flora defense mechanism, helping to  
maintain an acidic pH and providing competition for epithelial cell binding sites, thus 
reducing the probability of infection by invading microorganisms30.  Cytotoxicity testing was 
performed for PCL matrices using L. jensenii (ATCC 25258) which is a human vaginal 
isolate from a dominant species present in the human vagina. The purpose of the 
experiment was to determine whether any extractables were present in the PCL matrices 
that could inhibit growth of L. jensenii. Bacteria for use in the assay were cultured in MRS 
broth at 37°C under anaerobic conditions for 24 h and the culture was subsequently 
diluted to obtain an optical density of 1 using a spectrophotometer (Lovibond, Tintometer, 
Dormund) at 550 nm. The resulting suspension of lactobacilli (100 µL) was seeded in cell 
culture bottles containing 8 mL of MRS broth and 2 mL of SVF media that had contained 
PCL matrices. Samples were incubated for 24 h prior to determining cell growth by 
measuring the optical density at 550 nm. SVF incubation media in combination with MRS 
broth (1:4) served as the positive control and SVF served as the negative control.  
3.6 Shore hardness testing of PCL matrices 
The shore hardness of drug-free and doxycycline-loaded PCL matrices was measured 
using a CT3 Texture Analyzer (Brookfield Engineering Laboratories Inc., Middleboro, MA, 
USA). Cylindrical PCL matrices were mounted horizontally and compressed perpendicular 
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by using a 2 mm diameter, flat-ended, cylindrical probe (TA39) at a speed of 0.1 mm/min 
to depth of 2.0 mm. The shore hardness was calculated on the basis of force required to 
compress the matrix at a depth of 2 mm. The same test procedure was carried out on a 
pEVA IVR (Nuvaring®, Schering-Plough Pty limited, North Ryde, NSW, Australia) for 
comparison. 
3.7 In vitro doxycycline release  
A drug release study was performed in SVF on previously weighed cylindrical doxycycline-
loaded PCL matrices (length 45 mm) to simulate drug delivery from a section of a ring 
shaped device. Prior to release testing the ends of the matrices were sealed by dipping in 
5% w/v solution of PCL in acetone and then dried in air. Triplicate samples were placed 
separately in 10 mL of SVF and retained at 37°C in a temperature controlled incubator. 
SVF contained 3.51 g NaCl, 1.40 g KOH, 0.222 g Ca(OH)2, 0.018 g bovine serum albumin, 
2.00 g lactic acid, 1.00 g acetic acid, 0.16 g glycerol, 0.4 g urea and 5.0 g glucose in 2 L of 
distilled water. The pH was adjusted to 4.2 using 10% HCl27 and then filtered to remove 
any impurity. Each day the release media were collected and replaced with fresh SVF 
daily during the 14 days study. The drug concentration in the release media was analysed 
by using a Shimadzu HPLC equipped with binary pump and SPD-M20A photodiode array 
detector (50µl injection volume), 2.1 Χ 150 mm, 5 µm Agilent Extend C-18 (Agilent 
Technologies, CA, USA). Gradient elution was performed with water (eluent A) and 
acetonitrile (ACN, eluent B). The gradient was 15% (v/v) methanol in MilliQ water, 
increasing to 70% at 0.5 mL/min over 10 min, then held for 5 min, with the detection at 276 
nm and sample injection volume of 50 µL. Standard curves were generated using 
calibration samples ranging from 10-60 µg/mL. The amount of doxycycline contained in 
each sample of SVF release medium was obtained by comparison with the standard 
curve. Separate samples of release media were stored at 5°C until antibacterial activity of 
doxycycline released from the matrices has been tested on microorganisms. Blank PCL 
matrices were used as control and all the experiments were performed in triplicates. 
3.8 Assay of antibacterial activity of released doxycycline   
The antibacterial activity of doxycycline released from the PCL matrices into SVF was 
studied using Neisseria gonorrhoea using the disc diffusion method (M02-A10) established 
by the Clinical and Laboratory Standards Institute (950 West Valley Road, Suite 2500 
Wayne, PA 19087 USA)28. N. gonorrhoea was collected from an overnight culture in Heart 
Infusion broth (Oxoid) and diluted to an optical density of 1.0-1.1 at a wavelength of 600 
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nm (Lovibond, Tintometer, Dormund). Aliquots (100 µL) of the resulting suspension of N. 
gonorrhoea were spread evenly on Thayer Martin Agar. A blank disc (Oxoid) was placed 
at the centre of each inoculated plate and 50 µL of SVF containing doxycycline released 
from the PCL matrices along with standard samples comprising solutions of non-
formulated doxycycline in SVF (concentration range 30-150 µg/mL) were added to 
separate discs. Plates were incubated at 37°C for 24 h under modified atmospheric 
conditions containing 10% CO2 prior to measurement of the diameter of the zone of 
inhibition of test samples and standard (non-formulated) drug samples of the same 
concentration. SVF and release media that had contained drug-free PCL matrices were 
included as controls.  
3.9 Statistical analysis 
Significant difference in glass transition temperature, crystallinity and shore hardness were 
tested using one-way ANOVA with a Tukey multiple comparisons (p<0.05). 
4 Results and discussion 
Doxycycline-loaded PCL matrices, produced by rapidly cooling suspensions of the drug 
powder in PCL solution in acetone, present a uniform structure with an absence of cracks 
and voids in the sample surface and interior. The microporous morphology comprised 
irregular pore shapes with pore dimensions, generally in the range 1-5µm (Figure 1). The 
flat areas in Figure 1B and 1C may be formed by contact of polymer with the mould 
surface during matrix hardening. Large numbers of drug particles are visible on the matrix 
surface (Figure 1C) and in the matrix interior (Figure 1D). The shape and dimensions (10-
100 µm) of the doxycycline particles prior to matrix production are shown in Figure 1A. 
Comparison with drug-loaded matrices (Figure 1D and 1E) indicates that particulates were 
reduced in size during dispersion in the PCL solution as part of matrix production.  
A significant decrease in crystallinity of the PCL phase of 7% was measured on loading 
the PCL matrices with 15% w/w doxycycline in comparison with the blank PCL matrices 
(Table 1). Previous studies of microbicide-loaded PCL matrices have shown that the 
crystallinity of PCL may increase or decrease with increasing drug loading and the 
ordered, close-packed crystal lattice will, in turn, influence the transport of release medium 
and drug diffusion through the matrix. Loading progesterone into PCL at a concentration of 
10% also resulted in a decrease in crystallinity from 66% to 54%, possibly caused by 
inhibition of PCL nucleation and crystal growth by suspended drug particles29. In contrast, 
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metronidazole incorporation in PCL matrices increased the crystallinity of the PCL phase 
from 33% to 76% as the drug loading increased from 0 to 10.6% w/w25 and similar 
behaviour was recorded for gentamicin sulphate-loaded PCL matrices. This was explained 
in terms of the drug particles acting as nucleating agents for PCL crystal growth24.  
 
       
      
                                                                                                                                    
Figure 1: Morphology of PCL matrices revealed by scanning electron microscopy A) 
Doxycycline powder B) Surface of drug-free PCL matrix C) Surface of 10% 
doxycycline-loaded PCL matrix D) Interior of 10% doxycycline-loaded matrix E) 
Interior of 10% doxycycline-loaded matrix at higher magnification 
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Table 1: Thermal analysis and shore hardness of PCL matrices loaded with 
doxycycline. Data are the mean ± sd of 3 replicates. Values within columns that 
have the same superscript letter are not significantly different (p<0.05) 
Drug loading (% w/w) Glass transition 
temperature (°C) 
Crystallinity (%) Shore hardness 
(mN/mm2) 
0 64.8 ± 1.5a 80.2 ± 1.9a 1173 ± 15a 
5 71.2 ± 1.1b     79.0 ± 1.2a 1558 ± 30b 
10 68.9 ± 2.0b     77.0 ± 2.3ab 1758 ± 31c 
15 63.3 ± 1.3a     73.8 ± 1.5b 1937 ± 33d 
Thermograms obtained for doxycycline (Figure 2A) showed the prominent and typical 
endothermic peak at around 167°C which has been ascribed to crystal melting and the 
major exothermic peak at around 220°C due to thermal decomposition30,31. Dispersion of 
doxycycline in acetone followed by retention at -80°C resulted in the emergence of a 
broad, low endothermic peak at approximately 65°C in combination with the usual peak at 
167°C (Figure 2B). In other samples, only a single peak was observed at 65°C with 
disappearance of the endothermic peak at 167°C (Figure 2C), indicating gradual 
conversion to the lower melting point derivative. The explanation for this behaviour is 
unclear at present but gradual formation of a solvatomorph is suggested due to inclusion 
of acetone molecules in the doxycycline crystal lattice, resulting in a change in crystal 
structure and unit cell. This finding has implications for therapeutic efficacy due to the 
effect of different solid forms of a drug on dissolution behaviour for example.  
Thermograms of doxycycline-loaded PCL matrices displayed the prominent endothermic, 
melting peak at 60°C corresponding to melting of the PCL phase (Figure 2D).The melting 
peak of doxycycline at 167°C was not detected, possibly due to the low drug content of the 
matrix sample. However, a trace of the major exothermic peak at 220°C was in evidence. 
Detection of any endothermic peak at 65°C resulting from process-related changes in 
doxycycline’s crystal structure would be masked by the melting peak of PCL. 
65 
 
 
Figure 2: DSC thermogram of A) Untreated doxycycline powder B) Doxycycline 
powder (drug equivalent to 5% w/w doxycycline loading PCL dispersed in acetone 
and retained at -80°C) C) Doxycycline powder (drug equivalent to 10% w/w 
doxycycline loading PCL dispersed in acetone and retained at -80°C) D) 15% 
doxycycline-loaded PCL matrix. 
The favourable biocompatibility of PCL has been widely documented and underpins the 
extensive investigation of this polymer for drug delivery and tissue engineering 
applications. For example, cell viability of 95% was recorded when PCL microfibers were 
assessed using a  mouse fibroblast cell line32, while no significant effect on cell viability 
occurred when PCL nanoparticles were incubated with mouse embryonic fibroblast cells 
(NIH 3T3), human cervix carcinoma cells (HeLa) and human osteosarcoma cells 
(MG63)33. Recent studies have utilized the Vk2/E6E7 human vaginal cell line to assess the 
suitability of topical microbicides and other pharmacological agents intended for vaginal 
application34,35. In the present study Vk2/E6E7 cells were employed to identify possible 
detrimental effects on the vaginal epithelium due to the release of extractables from the 
matrix. SVF diluted with culture media 1:6 was used as the control and assigned the 
nominal value of 100%; all other data were normalized to this value and compared with it. 
Consequently, exposure of cells to the more favourable environment of culture media 
alone resulted in greater than 100% viability. SVF alone was found to cause a major 
reduction in Vk2/E6E7 cell viability due to its low pH of 4.2 and, with nonoxynol-9, acted as 
a negative control (Figure 3). No significant reduction in cell viability was recorded when 
samples of drug-free PCL matrix were incubated in SVF for 28 days and the incubation 
media (diluted 1:6 with culture media) was tested for Vk2/E6E7 cell viability (Figure 3) 
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indicating the favourable biocompatibility of PCL matrices for production of vaginal delivery 
devices.  
 
Figure 3: Viability of vaginal cell line VK2/E6E7 (ATCC® CRL 2616™) after exposure 
to simulated vaginal fluid (SVF) that had contained PCL matrices for 1 to 28 days 
(diluted 1:6 with culture media) (n = 3, mean ± s.d). SVF diluted with nutrient media 
(1:6), nutrient media alone and SVF were used as no treatment, positive and toxic 
controls, respectively. Data was compared to SVF + media (1:6) (*p<0.05, **p <0.01, 
***p <0.001).  
Lactobacilli are the most prevalent species in the vaginal environment and are considered 
important for maintaining the vaginal pH that acts as a major defensive mechanism against 
HIV and other pathogens36. It is important therefore that PCL matrices should not exhibit 
antimicrobial activity towards these commensal bacteria. No reduction in growth of L. 
jensenii was recorded when samples of PCL matrix were incubated in SVF for 28 days 
and the incubation media was tested against the lactobacilli in cell culture. An absence of 
significant levels of antimicrobial extractables is indicated, which provides further support 
for the favourable biocompatibility of PCL matrices and their intended application as 
vaginal delivery devices. 
The shore hardness of 15% w/w doxycycline-loaded matrices increased by approximately 
60% compared with drug-free matrices to around 1900 mN/mm2 (Table 1), indicating that 
the drug particles in the PCL matrix act as reinforcing agents. However, the shore 
hardness is still more than 4 times lower than poly (ethylene vinyl acetate) IVRs 
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(Nuvaring®) which were characterised by a  shore hardness value of 9280 mN/mm2. Thus 
doxycycline-loaded PCL matrices may be expected to provide improved user comfort 
compared with conventional IVRs. 
A burst release phase is evident over the first 24 h of testing when doxycycline-loaded 
PCL matrices were immersed in SVF at 37°C, resulting in a rapid loss of around 24-32% of 
the drug content (Figure 4A). Burst release is generally considered to result from 
dissolution of drug located at or close to the surface of the delivery device. Thus, the 
increase in burst effect with doxycycline loading of the matrices suggests a corresponding 
increase in surface presence of drug particles. Gradual drug release occurred over the 
following 13 days giving rise to an almost linear profile and total loss of 66-76% of the drug 
content.  In PCL matrices with lower drug loading, drug particles are more separated within 
the microporous PCL matrix compared with the higher drug loaded samples, resulting in 
extended diffusion path lengths and lower concentration gradients that contribute to a 
reduction in drug release. In the case of higher drug loading, in addition to the increased 
concentration gradient for drug diffusion, the increased number of drug particles within the 
PCL matrix may give rise to micro-cracking effects. This behaviour has been suggested to 
form a system of interconnected pores and channels which form a pathway for the entry of 
release media, leading to an increase in the rate of drug dissolution and release37. 
The minimum amount of drug released on day 11 into 10 mL of SVF from 5% w/w 
doxycycline-loaded matrices was 0.3 mg (Figure 4B). This data provides an estimate of 
the drug dose which would be delivered from a PCL IVR device in vivo and the drug 
concentration that would be produced in vaginal fluid for assessment of the antibacterial 
effect. 
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Figure 4: Cumulative (A) and amount (B) of doxycycline (DOX) release from PCL 
matrices into simulated vaginal fluid at 37°C  
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Figure 5: Antibacterial activity (%) of doxycycline released from 5% w/w 
doxycycline-loaded PCL matrices against Neisseria gonorrhoea relative to the 
standard non-formulated drug 
The antibacterial activity of doxycycline solutions (non-formulated) increased linearly with 
drug concentration with R2=0.9877 for the concentration range 30-150 µg/mL. The activity 
of doxycycline released from PCL matrices into SVF ranged from 90% on day 3 to 81% on 
day 14 (Figure 5) compared with non-formulated drug solutions of equivalent 
concentration. The small decrease in relative activity indicates that doxycycline is 
susceptible to degradation over time when exposed to SVF at 37°C within the matrix. The 
concentration of doxycycline in dry powder has been reported to reduce by 3% when 
stored at 40°C for 30 days20. The tetracyclines such as doxycycline hyclate are known to 
undergo reversible epimerisation at positions C-4 and C-6 under abnormal conditions of 
heat, pH and humidity to form a mixture of degradation products that have low antibiotic 
activity38. Thus the decrease in activity of doxycycline released from PCL matrices at 
extended time periods may be explained by gradual degradation associated with 
epimerisation.  
Given that the minimum daily concentration of drug released into SVF by 5% w/w 
doxycycline-loaded matrices is 30 µg/mL (Figure 4B), the cylindrical test samples used in 
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this study (4.5 cm long) correspond to approximately one third of the linear length of an 
IVR, and the turnover rate of vaginal fluid is approximately 8 mL/day27, the calculated 
minimum concentration of doxycycline released per day is 112.5 ug/mL. This far exceeds 
the minimum inhibitory concentration (MIC) against N. gonorrhoea (0.5-4.0 µg/mL)39, 
Chlamydia trachomatis (0.016-0.064 μg/mL)40 and Mycoplasma genitalium (0.125-0.25 
μg/mL)41. This basic modelling approach neglects the changes in volume and biochemistry 
of vaginal fluid over time (for example, pH), which will influence drug release kinetics and 
local drug concentration, but it illustrates the potential of these materials for maintaining 
elevated levels of anti-bacterial concentration and activity over extended periods of time in 
vaginal fluid. 
5 Conclusion 
PCL matrices loaded with doxycycline are able to deliver the drug efficiently for up to 14 
days in SVF with retained activity of 80-90% relative to (non-formulated) doxycycline 
solutions. The minimum concentration of released drug exceeded the MIC of doxycycline 
against many pathogens implicated in STIs. Biocompatibility studies of PCL further proved 
that the PCL is a safe polymer for the vaginal delivery as it has no effect on the vaginal 
cells and lactobacilli. These findings recommend further investigation of PCL matrices for 
vaginal delivery of antimicrobials as a strategy for local drug delivery, with the intention of 
improving patient compliance to reduce the risks of drug resistance and reinfection 
associated with long-term oral delivery. After studying the drugs individually further study 
was required to see the effect of combination of drugs on polymer and the release profile. 
In the next chapter, we tried to load combination of metronidazole and doxycycline. 
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CHAPTER 4  
SUSTAINED SIMULTANEOUS DELIVERY OF 
METRONIDAZOLE AND DOXYCYCLINE FROM 
POLYCAPROLACTONE MATRICES DESIGNED FOR 
INTRAVAGINAL TREATMENT OF PELVIC 
INFLAMMATORY DISEASE 
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1. Abstract 
Poly(ɛ-caprolactone) (PCL) matrices loaded with a combination of antibacterials, 
doxycycline and metronidazole, were produced by rapidly cooling a mixture of drug 
powders dispersed in 15% w/v PCL solution in acetone. Matrices loaded with different 
combinations of metronidazole (10, 15 and 20%) w/w and doxycycline (10%) w/w, 
measured with respect to the PCL content, were evaluated for release behaviour and 
antibacterial activity. Rapid ‘burst release’ of 8-15% of the drug content for doxycycline and 
31-37% for metronidazole was measured within 24 h when matrices were subjected to in 
vitro release testing in simulated vaginal fluid (SVF) at 37°C. The remaining drug was 
extracted gradually over 14 days to a maximum of 65-73% for doxycycline and 62-71% for 
metronidazole. High levels of antibacterial activity of up to 82-91% against Gardnerella 
vaginalis and 82-92% against Neisseria gonorrhoeae, were recorded in vitro for release 
media collected on day 14, compared to non-formulated metronidazole and doxycycline. 
The levels of both metronidazole and doxycycline released from PCL matrices into vaginal 
fluid in vivo were predicted to be greater by a factor of 2.5 and 7 than the minimum 
inhibitory concentrations for N. gonorrhea (0.5-4.0 µg/mL) and G. vaginalis (2-12.8 µg/mL) 
respectively, which are two of the major causative agents for pelvic inflammatory disease. 
These findings recommend in vivo investigations of PCL matrices loaded with a 
combination of doxycycline and metronidazole, in the form of intravaginal rings, for the 
treatment of pelvic inflammatory disease.  
2. Introduction 
Pelvic inflammatory disease (PID) is caused by migration of pathogenic and commensal 
microorganisms from the vagina or cervix towards the upper genital tract1,2. Neisseria 
gonorrhoeae, Chlamydia trachomatis and many anaerobic bacteria may be found  in the 
cervix, endometrium and fallopian tube of women suffering from PID and  are considered 
to be the major causative agents3. Many non-gonoccocal, non-chlamydial microorganisms 
such as Prevotella species, Gram-negative anaerobic rods, Peptostreptococcus sp., 
Gardnerella vaginalis, Escherichia coli and aerobic streptococci are recognized as 
contributing to bacterial vaginosis and, in the presence of cervical infection/inflammation, 
may ascend to the upper genital tract and become implicated in PID4. Signs of PID include 
inflammation of the upper genital tract, endometritis, salpingitis, and pelvic peritonitis and if 
not treated can cause tubo-ovarian abscess, tubal factor infertility, ectopic pregnancy and 
chronic pelvic pain5,6. 
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The most widely accepted treatment for PID involves oral doxycycline (100 mg) and 
metronidazole (400 mg) every 12 hours for a minimum of 2 weeks, since the combination 
displays activity against most of the bacteria that are the main causative agents for PID7, 8.  
However, patient non-compliance is common due to the long duration of treatment and the  
gastrointestinal side effects, oesophageal ulcers and bad taste associated with oral 
delivery of these drugs9, which may lead to repeated episodes of PID and consequently a 
higher risk of infertility and other complications10. The rate of infertility has been reported to 
increase from 8-12% for one PID episode to 40-50% for three PID episodes8. The risk is 
accentuated for young people due to a cervicovaginal environment that is more sensitive 
to infection, engagement in high-risk sexual behaviour6 and they are particularly non-
adherent to the therapy11. There is, therefore, an impetus to treat PID efficiently by 
developing a drug delivery system that increases patient acceptance and thus compliance. 
The vaginal route of drug administration has proven successful for contraceptive purposes 
(spermicidal and hormonal agents), potential prevention of HIV (tenofovir) and cancers of 
the reproductive tract (local delivery of cisplatin)12-16. Vaginal delivery offers widely 
recognized advantages over competing routes of administration including local drug 
delivery at the site of action in the case of HIV and other STIs, sustained drug delivery 
from controlled release devices, and the avoidance of gastrointestinal absorption and 
hepatic first pass effects leading to lower dosing and reduced side effects17. Vaginal 
delivery systems are available in the form of creams, gels, pessaries, films, tablets and 
intravaginal rings (IVRs). The advantages of IVRs over other approaches include the 
opportunity for sustained drug delivery and for avoiding the inconvenience and ‘messiness’ 
associated with insertion of semi-solid formulations (creams and gels)13. A year-long study 
carried out in 52 countries to check the efficacy, tolerability and acceptability of the 
Nuvaring® IVR revealed that out of the 806 women who completed the study, 96% 
expressed satisfaction with the ring performance and 98% would recommend the device to 
others18. In a randomized 12 week trial of the acceptability of silicone elastomer IVRs 
(without drug), involving HIV-negative women aged 18-35, of the 157 women who 
completed the trial, 96% reported finding the IVR acceptable for daily use19. Recent 
advances in IVR technology have demonstrated their potential utility for delivery of 
microbicides that can prevent the transmission of HIV/AIDS20,21, but the use of IVRs for the 
treatment of curable STIs has received comparatively little attention. 
The materials conventionally used for IVR production such as silicone elastomer and 
polyethylene vinyl acetate (pEVA) have the disadvantages of high processing 
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temperatures and hydrophobicity22. Silicone elastomer requires a curing reaction at 80°C, 
while pEVA is injection moulded at 140°C. Conversion of etonogestrel from the amorphous 
to the crystalline form at elevated processing temperatures has been reported on the 
surface of EVA copolymer at high drug loading23. Poly (ɛ-caprolactone) (PCL) offers 
advantages for the production of intravaginal drug delivery devices because of its 
biocompatibility, ease of processing and relatively low processing temperatures24. PCL has 
already been widely studied for controlled drug delivery in the form of micro- and 
nanoparticles, fibers and matrices25. In particular, PCL matrices prepared by rapid cooling 
techniques have been investigated for controlled vaginal delivery of individually loaded 
antibacterials (gentamicin and norfloxacin)26,27 antifungal agents (miconazole)27 and 
antiviral agents (tenofovir and acyclovir)28,29. Here we describe sustained, simultaneous 
delivery of metronidazole and doxycycline hyclate from PCL matrices containing both 
drugs. The materials are intended for production of IVRs in the treatment of PID, where 
doxycycline and metronidazole are active against most of the bacteria that are the main 
causative agents. 
3. Materials and methods 
3.1 Materials 
PCL (Mw 115,000 Da, CAPA 6500) was obtained from Solvay Interox, Warrington, UK. 
Doxycycline hyclate was purchased from Alfa Aesar (Ward Hill, MA, USA) and 
metronidazole, sodium chloride, potassium hydroxide, calcium chloride, bovine serum 
albumin, glucose, glycerol, urea, lactic acid and acetic acid were purchased from Sigma 
Aldrich (Castle Hill, NSW, Australia). Solvents (acetone, acetonitrile) were of analytical 
grade. Gardnerella vaginalis stock culture in glycerol broth was supplied by Micromon, 
Monash University, Clayton, VIC, Australia. Horse blood agar, heart infusion broth (HIB), 
and CO2 generating kit sachets were obtained from BD (New Jersey, USA), and Thayer 
Martin Agar and MRS broth from Micromedia, VIC, Australia. Neisseria gonorrhoeae 
NG1291 was provided by the School of Chemistry and Molecular Bioscience, the 
University of Queensland (UQ), Australia. Lactobacillus jensenii ATCC 25258, a human 
vaginal isolate, was sourced from the School of Agriculture and Food Sciences, UQ. The 
human vaginal epithelial cell line Vk2/E6E7 (ATCC® CRL2616™), 
Dulbecco's modified Eagle's media / F12 Media and DMSO were purchased from 
American Type Culture Collection (Manassas, Virginia, USA). Keratinocyte, serum-free 
79 
 
media (GIBCOTM), human recombinant EGF, bovine pituitary extract, penicillin and 
streptomycin (P/S) were purchased from Sigma-Aldrich, Australia. 
3.2 Production of PCL matrices loaded with metronidazole and doxycycline hyclate 
in combination  
Cylindrical PCL matrices loaded with combinations of metronidazole and doxycycline 
hyclate were prepared according to our previously reported method (Chapter 2). A 15% 
w/v solution of PCL in acetone was produced by heating at 45°C for 45 min. Finely ground 
doxycycline and metronidazole powder were added to attain a drug loading of 10, 15 and 
20% w/w metronidazole and 10% w/w doxycycline, measured  with respect to the weight 
of PCL. A large burst effect has been observed for PCL matrices loaded only with 
metronidazole (35-65%) along with low drug release rates over a period of 14 days 
(Chapter 2), while in contrast doxycycline release from single-loaded PCL matrices was 
more consistent (Chapter 4), resulting in gradual delivery of 65-75% of the drug load over 
14 days. Thus PCL matrices were loaded with increasing concentrations of metronidazole 
at constant doxycycline loading in the present study to focus on enhancing the rate and 
quantity of metronidazole release. The resulting drug suspension in PCL solution was 
poured into 3 mL polypropylene syringes as a mould and cooled rapidly at -80°C to induce 
crystallisation of the PCL phase. After retention at -80°C for 24 h the resulting PCL 
matrices were removed from the moulds and dried for 24 h under ambient conditions to 
evaporate solvents. The resulting cylindrical matrices had a diameter 6.3 ± 0.5 mm and 
length 45 ± 3 mm.  
3.3 Morphology of drug-free and drug-loaded PCL matrices 
Scanning electron microscopy (SEM) (JEOL-6610LV SEM, Jeol Ltd., Tokyo, Japan) was 
performed on drug-free and drug-loaded PCL matrices to examine the morphology of the 
matrices and the drug distribution within the matrix. Thin sections were mounted onto 
aluminum stubs using adhesive carbon tabs and sputter coated with platinum using an 
Eiko sputter coater prior to examination in the SEM at 10 kV.  
3.4 Thermal properties of drug-free and drug-loaded PCL matrices 
Differential scanning calorimetry (DSC) (DSC 1 STARe System, Mettler-Toledo Ltd., 
Victoria, Australia) was used to study the thermal properties of drug-free and drug-loaded 
PCL matrices.  Samples (approximately 5 mg, accurately weighed) were sealed in 
aluminium pans and heated over the temperature range 30-330°C at a rate of 10°C/min. 
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The glass transition temperature (Tg), and crystallinity data were obtained using the DSC 
software facility. The percentage crystallinity of the PCL phase was estimated using a heat 
of fusion of 139.5 J/g for the fully crystalline polymer 26. 
3.5 In vitro release behaviour of metronidazole and doxycycline from combination-
loaded PCL matrices 
Triplicate samples of drug-free and drug-loaded cylindrical matrices (6.3 mm diameter,  
and 45 mm  length) containing metronidazole and doxycycline in combination were 
weighed and the ends were sealed using 5% w/v solution of PCL in acetone. Individual 
samples were placed in 10 mL of SVF and incubated at 37°C for 14 days. Release media 
were collected daily and replaced with fresh media. The concentration of metronidazole 
and doxycycline in the release media was measured using a Shimadzu HPLC equipped 
with binary pump and SPD-M20A photodiode array detector, and 2.1 Χ 150 mm, 5 µm 
Agilent Extend C-18 (Agilent Technologies, CA, USA). Gradient elution was performed 
using water (eluent A) and acetonitrile (ACN, eluent B) with 15% ACN  concentration, 
increasing to 70% at 0.5 mL/min over 10 min, then held for 5 min. Detection was 
performed at 276 nm for doxycycline and 320 nm for metronidazole. Standard curves were 
generated for each drug using calibration samples ranging from 10-100 µg/mL and the 
concentration of each drug in the release media was obtained by comparison with the 
standard curve. Separate samples of release media were stored at 5°C prior to assay of 
antibacterial activity.  
3.6 Antibacterial activity of metronidazole and doxycycline released from PCL 
matrices 
The antibacterial activity of SVF release media collected over 14 days for PCL matrices 
loaded with 10% metronidazole and 10% doxycycline was assayed against G. vaginalis 
and N. gonorrohoeae using the disc diffusion method. The antibacterial activity of 
metronidazole and doxycycline in the release media was compared with the same 
concentration of non-formulated metronidazole or doxycycline dissolved in SVF. G. 
vaginalis was grown for 48 h at 37°C under anaerobic condition on horse blood agar plates 
while N. gonorrohoeae was grown on Thayer Martin agar plates for 24 h at 37°C under 
10% CO2. Colonies of both microorganisms were collected in HIB by scraping from the 
agar surface.  The suspensions of G. vaginalis were subsequently diluted in HIB such that 
100 µL plated on horse blood agar resulted in 100 colony forming units (CFU); the colonies 
for this strain were large and spreading and thus only a low inoculum was needed. The cell 
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suspension of N. gonorrohoeae was diluted to obtain an optical density of 1 at 550 nm and 
100 µL of the suspension was spread on Thayer Martin agar. The disc diffusion assay was 
performed by placing a blank disc (Oxoid) at the center of each inoculated plate and 
adding 100 µL of SVF release media or non-formulated drug solution (standard) of the 
same concentration. Plates were incubated for 24 h and the diameter of the zone of 
inhibition surrounding each disc was measured. The relative antibacterial activity (%) of 
metronidazole and doxycycline released from the PCL matrices was obtained by 
comparing the zone of inhibition with that of non-formulated drug samples of equivalent 
concentration. SVF alone and SVF release media that had contained blank PCL matrix 
were used as controls. 
4. Results and Discussion 
4.1 Morphology of PCL matrices 
PCL matrices containing doxycycline and metronidazole in combination were produced 
successfully by rapidly cooling a suspension of both drugs in PCL solution, and presented 
as uniform cylindrical mouldings with an absence of cracks and voids in the interior and on 
the surface. SEM examination revealed large numbers of drug crystals of size around 5 
µm on the surface of PCL matrices (Figure 1A). Although it is not possible to distinguish 
between metronidazole and doxycycline crystals in the micrograph, the greater burst 
release of metronidazole (Section 4.5) suggests that the crystals are likely to be 
metronidazole. The size and morphology of metronidazole (100 µm) and doxycycline (10 
µm) particulates used in  matrix production are revealed in Figure 1D and 1E, respectively, 
indicating that the drug crystals are broken down during matrix formation production. The 
highly porous morphology of the PCL matrices revealed (Figure 1B) may be expected to 
facilitate gradual release of both antibacterials. The pore sizes ranged between 2-4 µm 
and a similar morphology is visible in the drug free PCL matrix (Figure 1C).  
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Figure 1: Scanning electron micrographs  of PCL matrices A) Surface and B) Interior 
of PCL matrices loaded with 10% metronidazole, 10% doxycycline loaded PCL 
matrix C) Surface of blank PCL matrix D) Metronidazole crystals E) Doxycycline 
crystals 
4.2 Thermal analysis 
Thermal analysis of PCL matrices loaded with a combination of metronidazole and 
doxycycline revealed a small increase in glass transition temperature (Tg) of the PCL 
phase at the highest drug loading (Table 1) which may be explained by the reinforcing 
effect of the particulates and restriction of polymer chain mobility. The crystallinity of the 
PCL phase of drug-loaded matrices is expected to influence release characteristics and 
thus therapeutic efficacy; fluid transport is impeded by a close packed crystal structure, 
resulting in changes in drug dissolution and diffusion kinetics31. Crystallinity of the PCL 
phase was reduced by over 50% on incorporation of both metronidazole and doxycycline 
at loadings of 10% w/w (Table 1), indicating interference with PCL crystal nucleation and 
growth. When loaded individually into PCL, as loading increases, doxycycline reduces 
crystallinity (Chapter 3) while metronidazole increases crystallinity (Chapter 2) in 
comparison to drug-free PCL matrices. Indeed, in the present study PCL crystallinity 
increased as the concentration of metronidazole loaded into the matrices increased from 
A B C 
D E 
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10 to 20% (Table 1), supporting the hypothesis that metronidazole acts as a nucleating 
agent for crystallisation of PCL. The increase in PCL crystallinity in matrices incorporating 
both metronidazole and doxycycline is less than with metronidazole alone (Chapter 2), 
providing further evidence that doxycycline is opposing the effect of metronidazole by 
restricting crystallisation of PCL (Chapter 3).  
Table 1: Thermal analysis of PCL matrices loaded with a combination of 10, 15 and 
20% w/w metronidazole (MTZ) and 10% w/w doxycycline (DOXY). The numbers 
sharing the same superscript letter are not significantly different (P<0.05). 
 
Drug loading (w/w) Glass transition temperature 
(°C) 
Crystallinity (%) 
Drug-free -64.1 ± 1.3a 82.3 ± 4.3a 
10% DOXY + 10% MTZ -63.8 ± 2.1a 30.6 ± 0.9b 
10% DOXY + 15% MTZ -64.1 ± 0.8a 40.6 ± 2.4c 
10% DOXY + 20% MTZ -66.4 ± 1.1a 52.8 ± 1.3d 
4.3 Release behaviour of doxycycline and metronidazole from PCL matrices loaded 
with a combination of both drugs  
Cumulative release of metronidazole from PCL matrices loaded with a combination of 
metronidazole and doxycycline was characterized by a significant burst effect resulting in 
rapid loss of around 30-35% of the metronidazole content during the first 24 h in SVF 
(Figure 3A).  
Gradual drug release occurred over the following 13 days resulting in delivery of 60-70% 
of the drug content. The amount of metronidazole released increased as drug loading in 
the matrix increased, indicating a diffusion-dominated release mechanism controlled by 
the drug concentration gradient. In the case of doxycycline, 8-15% release occurred in the 
first 24 h, which was smaller than that recorded in PCL matrices loaded with doxycycline 
alone (Chapter 4) and may indicate that the drug particles observed on the surface of the 
PCL matrices (Figure 2A) were predominantly metronidazole. Drug release occurred 
gradually until day 8 and then slowed, resulting in delivery of 65-75% of the doxycycline 
content after 14 days in SVF (Figure 2B). Doxycycline release increased with increasing 
loading of metronidazole, which may be explained by the formation of increasing numbers 
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of pores and channels as the drug loading in the matrix increased, facilitating ingress of 
SVF, and dissolution of drug particles and transport of drug molecules from the matrix.  
 
 
 
Figure 2: Cumulative release (% of total) into simulated vaginal fluid at 37°C of A) 
Doxycycline B) Metronidazole from PCL matrices loaded with a combination of 
metronidazole (MTZ) and doxycycline (DOXY) 
 
The absolute amount of metronidazole and doxycycline released over time from PCL 
matrices loaded with a combination of both drugs is presented in Figure 3A and B 
respectively, which is useful for estimating the delivered dose from PCL matrices and for 
predicting the in vivo concentration of antibacterials in vaginal fluid. Approximately 15 mg 
of metronidazole was released into 10 mL of SVF at day 1 from matrices loaded with 10% 
w/w metronidazole and 10% w/w doxycycline and the amount fell to around 1 mg at day 
14. Doxycycline release was lower in day 1 (5 mg) reflecting the lower burst effect but 
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reached a similar level to metronidazole at day 14. An erratic ‘cyclical’ release behaviour of 
doxycycline (Figure 3A) may reflect the lower solubility of doxycycline in SVF compared 
with metronidazole. The process of doxycycline release may be controlled by dissolution 
and release of metronidazole that subsequently permits ingress of SVF and dissolution of 
doxycycline particles. Overall, it is apparent that PCL matrices loaded with a combination 
of doxycycline and metronidazole are able to deliver both drugs gradually into SVF for 14 
days with a relatively high delivery efficiency of 70%. 
 
 
Figure 3: Amount (mg) A) of Doxycycline (DOXY) and B) Metronidazole (MTZ) 
released daily from PCL matrices into the 10 mL simulated vaginal fluid at 37°C 
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4.4 Antibacterial activity of metronidazole and doxycycline released from PCL 
matrices against G. vaginalis and N. gonorrhoeae 
The antibacterial activity of metronidazole and doxycycline released on day 14 from PCL 
matrices loaded with a combination of both compounds was assessed to investigate the 
effect of matrix production and residence time in SVF on antibacterial activity. Zones of 
inhibition for G. vaginalis cultures on agar increased linearly from 7 to 20 mm when 
increasing concentrations of non-formulated metronidazole in SVF (25-125 µg/mL) were 
applied. Similarly, the zone of inhibition for N. gonorrhoeae cultures on agar increased 
linearly from 17-28 mm when increasing concentration solutions of non-formulated 
doxycycline in SVF (20-100 µg/mL) were applied. No zone of inhibition was observed for 
SVF alone or release media obtained from drug-free PCL matrices. High relative 
antibacterial activity was measured for SVF containing metronidazole and doxycycline 
released from PCL matrices loaded with both drugs at a 10% loading level; activity was 
86-96% with respect to non-formulated metronidazole and 84-92% with respect to non-
formulated doxycycline (Figure 4). The relatively small decrease in antibacterial activity 
over the course of the study may be due to prolonged exposure of the antibacterials within 
the PCL matrix to warm temperature (37°C) and SVF causing partial degradation. The 
tetracyclines such as doxycycline hyclate are known to undergo reversible epimerisation at 
positions C-4 and C-6 under abnormal conditions of heat, pH and humidity to form a 
mixture of degradation products that have low antibacterial activity (Chapter 3), and a 1% 
reduction in metronidazole content has been reported when subjected to accelerated 
stability conditions of pH 2-6 at a temperature of 25 and 37°C in aqueous conditions32.  
The minimum daily amount of metronidazole and doxycycline released from PCL matrices 
(length 45 mm) into 10 mL SVF was measured as 30 µg metronidazole at day 11 from 
15%MTZ+10%DOXY w/w matrices and 27 µg doxycycline at day 13 from 
20%MTZ+10%DOXY w/w matrices (Figure 3A and B). Based on this, the estimated drug 
concentrations that would be generated in vaginal fluid in vivo using an IVR produced from 
a PCL matrix, is anticipated to far exceed the minimum inhibitory concentration (MIC) for 
metronidazole against G. vaginalis (2–12.8 µg/mL)33. Similarly, the MIC for doxycycline 
against N. gonorrhoea (0.5-4.0 µg/mL)34, Chlamydia trachomatis (0.016-0.064 μg/mL)35 
and Mycoplasma genitalium (0.125-0.25 µg/mL)36 would be exceeded. These predictions 
are based on the linear length of an IVR of 150 mm and a vaginal fluid turnover rate of 8 
mL per day37 and neglects the complex changes in vaginal fluid over time (for example, 
pH, biochemistry and volume) that may influence drug release behaviour. However, the 
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demonstrated drug release and activity profiles in vitro underline the potential of PCL 
matrices for sustained intravaginal delivery of a combination of antibacterials for the 
treatment of PID. 
 
Figure 4: Relative antibacterial activity of doxycycline (DOXY) and metronidazole 
(MTZ) released from PCL matrices incorporating both antibacterials compared with 
the non-formulated drugs 
5. Conclusion 
PCL matrices loaded with metronidazole and doxycycline in combination provide 
simultaneous and sustained release of each antibacterial for up to 14 days in simulated 
vaginal fluid with antibacterial activity against G. vaginalis and N. gonorrohoeae in excess 
of 80% of the non-formulated drugs. The concentration of metronidazole and doxycycline 
achieved in vitro exceeded the MIC required to eradicate many pathogens implicated in 
PID. Good drug loading obtained for the combination of two drugs further confirming the 
suitability of the improved production method. The above results again confirm the 
suitability of PCL polymers for the delivery of combination of antibacterials. 
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CHAPTER 5  
INVESTIGATION OF INTRAVAGINAL DELIVERY OF A 
MACROMOLECULE USING POLYCAPROLACTONE  
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1. Abstract 
Polycaprolactone (PCL) matrices loaded with lactoferrin, as a model macromolecule, were 
prepared using a rapid cooling method. Matrices loaded with 5% and 10% w/w lactoferrin 
were studied for matrix properties and lactoferrin release. A comparatively fast release of 
around 13-14% occurred on day 1, with 90-95% protein being released within 14 days in 
simulated vaginal fluid (SVF) at 37°C. Using SDS-PAGE, it was determined that the 
lactoferrin released from PCL matrices into SVF was intact. Differential scanning 
calorimetry indicated a decrease of 6% in crystallinity and hardness testing showed that 
there was a 58% decrease in shore hardness for matrices loaded with 10% w/w in 
comparison to blank matrices, which suggests that lactoferrin causes some deterioration of 
polymer properties.  
2. Introduction 
Vaginal drug delivery systems have been used for contraception and for treatment and 
prevention of sexually transmitted infections. The vagina has potential as a drug delivery 
route for other medications because of its advantages over the other delivery routes such 
as avoidance of first pass metabolism, avoidance of GI side effects and less frequent and 
lower dosing1. The delivery of drugs used for the treatment of sexually transmitted 
infections through vaginal route also have the advantage of target delivery at the entry 
point of pathogens and direct contact of the drugs with the infected cells2. Many new drugs 
of biotechnological origin such as Enfuvirtide, 2F5 and recombinant proteins gp160, gp140 
and gp413-5 for the treatment of sexually transmitted infections are macromolecular in 
nature and new strategies are being investigated toward the delivery of these 
macromolecular drugs related with the prevention and treatment of STIs in an efficient and 
safe way through the vaginal route6.  
Recently, it has been reported that monoclonal antibodies (mAbs) such as 2F5, 4E10 and 
2G12 protected macaques from the simian/human immunodeficiency viral (SHIV) 
challenge on IV, oral, rectal and vaginal application7-9. These mABs were found to be 
active against a wide variety of HIV isolates so could be potential for the treatment of 
HIV10. 5P12-RANTES and 6P4-RANTES are two recombinant proteins isolated from 
human chemokine proteins PSC-RANTES, found to exhibit anti-HIV by blocking the HIV 
coreceptor CCR511. Attempts have been made to delivery various therapeutically 
important drugs such as insulin, calcitonin and sex hormones via the vaginal route but 
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there has been little success in the development of safe and viable vaginal formulations for 
these macromolecular drugs.  
The human vagina is considered to be an alternative route for the delivery of various 
macromolecules such as insulin, calcitonin and sex hormones12 and it has been found that 
molecular weight cut-off for vaginal mucosa is much higher than the other mucosal 
routes13. Many attempts have been made to deliver macromolecules for the treatment of 
sexually transmitted infections. CN54gp140, which is a HIV-1 envelope glycoprotein, has 
been delivered as a lipososme gel formulation in order to develop vaccination against HIV-
1. An encapsulation efficiency of 35% was reported and the protein maintained more than 
80% of their antigenicity14. Niosomes containing insulin prepared using sorbitan monoester 
as a carrier and by lipid evaporation, had entrapment efficiency of 17-28% and 30% of the 
entrapped insulin was released within 25 h. When these niosomes were studied for their 
efficiency in controlling blood glucose level in mice it was found that maximal 
hypoglycemic effects (a decrease of 46%) were observed within 1.5 h and the effect was 
retained for 6 hrs15.  
Intravaginal rings (IVRs) are considered to be the most acceptable and efficient vaginal 
drug delivery system for the delivery of many drugs such as antifungals, contraceptives 
and drugs related with HIV prevention1. They are particularly more acceptable because of 
ease of insertion, long term sustained delivery and avoidance of messiness caused by 
other conventional vaginal preparations such as vaginal creams16. The concept of 
delivering macromolecular drugs from IVRs is not new; previously protein antigen BSA in 
the form of inserts has been delivered using silicone elastomer with 80% protein release 
over a 12 week period and good protein stability17. Similarly a 10-pod insert IVR for the 
delivery of antibody IgG sustained in vitro release of 0.5-30 mg/day for 14 days and the 
IgG retained activity during the release period according to an ELISA test18.  
Currently polymers that are used in the manufacturing of intravaginal rings are silicone and 
polyethylene vinyl acetate, but these are almost impermeable to macromolecular drugs 
and are non-biodegradable. Polycaprolactone (PCL) on the other hand is a highly porous 
material that has been investigated for the intravaginal delivery of small molecules such as 
metronidazole and/or doxycycline for the treatment of sexually transmitted infections 
(Chapters 2-4). PCL never studied for the intravaginal delivery of macromolecules. The 
aim of the current study was to investigate PCL as a potential polymer for the delivery of a 
macromolecule. In the current study lactoferrin was used as a model macromolecule. 
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Lactoferrin (LF) is an 80 kDa iron-binding glycoprotein of the transferrin family that is 
expressed in most biological fluids and is a major component of the mammalian innate 
immune system19. This glycoprotein is found in mucosal secretions, including tears, saliva, 
vaginal fluids, semen, nasal and bronchial secretions, bile, gastrointestinal fluids, urine and 
most highly in milk and colostrum20. 
3. Materials and methods 
3.1 Materials 
Polycaprolactone (PCL, MW 115,000 Da, Capa 650) was obtained from Solvay Interox 
(Warrington, UK). Bovine lactoferrin was a gift from Dr. Nidhi Bansal (Lecturer, School of 
Agriculture and Food Science, University of Queensland). Sodium chloride, potassium 
hydroxide, calcium chloride, bovine serum albumin, glucose, glycerol, urea, lactic acid and 
acetic acid were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia). Solvents 
(acetone, acetonitrile) were of analytical grade and obtained from purchased from Sigma-
Aldrich, Australia. 2X Laemmli sample buffer, 12% SDS precasted 15 well gels were 
purchased from Bio-Rad (Gladesville, NSW, Australia). PageRuler plus prestained protein 
ladder was purchased from ThermoFisher Scientific (Scoresby, Vic, Australia). 
3.2  Preparation of lactoferrin-loaded PCL matrices 
1.5 g of PCL melted in 10 mL acetone at 45°C for 45 min. Once melted the resulting 
suspension was taken away the heat source and allowed to cool to 40°C to prevent the 
lactoferrin from excess of heat, and lactoferrin powder was dispersed into polymer 
suspension to produce protein loading of 5% and 10% w/w with respect to PCL content. 
Solid matrices of the polymer were obtained using 3 mL polypropylene syringe barrels as 
moulds as previously described (Chapter 4 and 5). The final matrices were in the form of 
cylinders of diameter 6.3 ± 0.2 mm and length 45.0 ± 3.0 mm. 
3.3  Morphology 
JEOL-6610LV scanning electron microscopy (SEM) (Jeol Ltd., Tokyo, Japan) was used to 
study the morphology of lactoferrin loaded PCL samples. Small samples were cut from the 
surface and inside the PCL matrices and fixed onto aluminum stubs and then coated using 
an Eiko sputter coater automatic mounting press. Coated samples were then studied for 
their surface and interior morphological characteristics using a voltage of 10 kV.  
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3.4 Thermal analysis 
Differential scanning calorimetry (DSC) (DSC 1 STARe System, Mettler Toledo, Mettler-
Toledo Ltd., Victoria, Australia) was used to study the effect of lactoferrin loading on the 
PCL matrices. Small pieces of PCL matrices loaded with lactoferrin were cut, weighed, 
sealed inside alumina pans. Samples were heated across the temperature range 30-
330°C at a rate of 10°C/min. The glass transition temperature (Tg), and crystallinity data 
were obtained using the DSC software.  
3.5 Shore hardness 
Shore hardness of the of drug-free and lactoferrin-loaded matrices was carried out using a 
CT3 Texture Analyzer (Brookfield Engineering Laboratories Inc., Middleboro, MA). 
Cylindrical PCL matrices were mounted horizontally and compressed locally at a speed of 
0.1 mm/min to a depth of 2.0 mm using a 2 mm diameter, flat-ended, cylindrical probe 
(TA39). The shore hardness (or indentation resistance) of each sample was calculated 
from the applied force measured at a depth of 2 mm. A pEVA IVR (Nuvaring®, Schering-
Plough Pty limited, New South Wales, Australia) was subjected to the same test procedure 
for comparison. 
3.6 In vitro lactoferrin release 
Release of lactoferrin from PCL matrices was tested in simulated vaginal fluid (SVF) as the 
release media. Ends of the matrices were sealed with 5% w/v PCL solution to mimic the 
ring characteristics and to avoid any edge release of lactoferrin. Samples were put into 10 
mL of SVF in an incubator at 37°C for 14 days. Each day samples of SVF containing 
released lactoferrin were collected and replaced with fresh 10 mL SVF. The concentration 
of lactoferrin in collected media was analyzed by using Shimadzu HPLC equipped with 
binary pump and SPD-M20A photodiode array detector. Separation was carried out using 
an Agilent Extend C-18 column (2.1 x 150 mm, 5 µm). Two mobile phases were used, 
water (eluent A) and 95% acetonitrile (eluent B), both with 0.1% (v/v) trifluoroacetic acid 
added A gradient elution started at 15% B  and reached 70% B at 10 min and held at this 
level for 5 min. The column was re-equilibrated at 15% B for 10 min between runs.  
The sample injection volume was 50 µl and the quantification of lactoferrin was performed 
at 276 nm against a standard curve for the concentration range 10-60 µg/ml (R2 = 0.9988). 
Each experiment was performed in triplicate. Release samples were stored at 0°C for 
antibacterial testing. 
96 
 
3.7 SDS-PAGE of released lactoferrin 
Small discs of PCL matrices loaded with 5% and 10% w/w lactoferrin were cut and 
incubated with 10 ml of SVF at 37°C for 14 days and the media then collected and tested 
for the stability of protein. 5 μL of the release media containing lactoferrin was mixed with 5 
μL of sample buffer (4.5 μL of 2x Laemmli Sample Buffer and 0.5 μL of beta 
mercaptoethanol). 5 μL of the mixture was added into each well of a 12% SDS-PAGE gel 
and electrophoresis was performed according to Laemmli (1970)21. 
3.8 Statistics 
Significant difference in glass transition temperature, crystallinity and shore hardness were 
tested using one-way ANOVA with a Tukey multiple comparisons test (p<0.05). 
4. Results and discussion 
4.1  Morphology of the PCL matrices 
PCL matrices produced by rapid cooling exhibited a porous morphology with many 
interconnected pores and channels. The pore size in the case of blank matrices was 3-5 
µm (Figure 1a) but this increased to 6-10 µm when lactoferrin was loaded (Figure 1b). 
Lactoferrin crystals, which vary in size from 0.5-3 µm (Figure 1c), were present on the 
surface of the matrix. 
         
Figure 1: Surface view of a) Blank PCL b) PCL loaded with 5% w/w lactoferrin c) 
lactoferrin crystals 
4.2 In vitro release characteristics 
A fast release of lactoferrin was observed for the first 2 days for matrices loaded with 5% 
lactoferrin, and for the first 4 days for matrices containing 10% lactoferrin (Figure 2). 
Thereafter release occurred more slowly until 90-95% of lactoferrin had been released by 
the end of the 14 day test period. The more prolonged burst release exhibited by the 10% 
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lactoferrin-loaded matrices resulted in 70% release occurring by 4 days, while the slower 
release of the 5% lactoferrin-loaded matrices reached 70% at 7 days. The difference is 
due to more drug being available in the case of the higher loading.  Initial faster release is 
a common feature of these types of polymeric systems and can be due to lactoferrin 
molecules coming to the surface of the polymer during the crystallization process. Gradual 
release of the protein is expected through the interconnected pores and channels in 
microporous PCL matrices and due to the microcracking effect on the internal structure of 
the polymers caused by protein particles22. 
Lactoferrin maintained its molecular size during matrix production and release into SVF. 
One protein band was observed for lactoferrin using SDS-PAGE electrophoresis, at a 
comparable location to lactoferrin standard (Figure 3), indicating that the structure of the 
protein that was released from PCL matrices into SVF over a 14 day period of time was 
not degraded into subunits. This assessment does not indicate the maintenance of activity, 
and this would be important to determine if a protein is to be loaded with an specific 
activity in mind; in this case lactoferrin was used as a model protein and this initial data 
indicates that the protein retained its structure. There is no previous research using 
lactoferrin with PCL, but using another model protein, bovine serum albumin, stability 
when released from PCL scaffolds formed by melt extrusion and PCL microparticles 
prepared by a w/o/w method was confirmed using circular dichroism23,24. 
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Figure 2: Cumulative release of lactoferrin (% of total loaded) from PCL matrices 
containing 5 or 10% w/w lactoferrin, measured in SVF at 37°C for 14 days. 
          
Figure 3: SDS-PAGE of lactoferrin (80 kDa): 1) Molecular weight biomarker ladder 2) 
lactoferrin standard 3) 5% w/w and 4) 10% w/w of lactoferrin after release from the 
PCL matrices into simulated vaginal fluid over 14 days. 
4.3 Thermal characteristics and shore hardness 
It is very important to study the effect of lactoferrin on the PCL polymer as it affects 
polymer degradation and hardness, and lactoferrin release. The main features that 
represent the thermal behaviour of the polymer are crystallinity and glass transition 
temperature. The effect of drug loading on the polymer can be studied by comparing the 
values with the blank polymer. A reduction in crystallinity of around 6% occurred when the 
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concentration of lactoferrin increased from 5 to 10% w/v (Table 1). The reduction in 
crystallinity indicates that protein molecules are interfering with crystal growth and 
nucleation of PCL. 
Glass transition temperature (Tg) indicates the reversible change of the amorphous region 
of a polymer from viscous, to rubbery, and finally to a hard and brittle condition. There was 
a large (10°C) difference in Tg between blank matrices and lactoferrin-loaded matrices 
(Table 1), but minimal difference when the concentration of lactoferrin was increased from 
5 to 10% w/v. This indicates that dispersing lactoferrin molecules into the PCL had an 
effect on PCL chain mobility. The crystallinity of the polymer decreased when the 
concentration of the polymer increased (Table 1) which might be due to suspended 
lactoferrin inhibiting PCL nucleation and crystal growth. The effect of added molecules on 
PCL matrix crystallinity varies with molecule loaded, as doxycycline caused a decrease in 
crystallinity of around 5% on increasing the concentration from 5% to 15% w/w (Chapter 3) 
but metronidazole loading was associated with an increase in crystallinity from 33% to 
76% with increasing metronidazole loading of the material from 0 to 8.1% w/w (Chapter 2). 
Matrix shore hardness decreased as lactoferrin loading increased (Table 1), representing 
the increasing amount of protein particles in the polymer having an increased reinforcing 
effect resulting in a softer matrix. However, the shore hardness of the material is far lower 
that one of the commercial vaginal rings available in the market i.e. Nuvaring®, for which 
shore hardness measured 9280 mN/mm2 using the same method (Chapter 2). Using a soft 
material such as PCL will ensure the rings will be more comfortable to use then the 
conventional vaginal rings.   
Table 1: Thermal and morphological analysis of PCL matrices loaded with 
lactoferrin. Within each column, numbers sharing the same superscript letter are 
not significantly different (P<0.05). 
Protein loading 
(%w/w) 
Glass  transition 
Temperature (°C) 
Crystallinity (%) Shore Hardness 
(mN/mm2) 
          0        -66.48 ± 1.2a 82.32 ± 2.3a 1382 ± 132a 
          5       -55.23 ± 0.8b 82.10 ± 4.6a 1097 ± 87b 
         10        -55.91 ± 0.9b 76.72 ± 3.3a 810 ± 62c 
100 
 
5. Conclusion 
PCL matrices are capable of loading lactoferrin without affecting its structural integrity. 
Extended release of lactoferrin over 14 days in SVF is possible. Lactoferrin is reported to 
have activity against many pathogens responsible for STIs20, 25, 26 so could be a useful 
model for further investigation. This study provides avenues for further investigation into 
the use of this polymer in form of IVRs for delivering macromolecules for the treatment and 
prevention of sexually transmitted infections. In the current study we used SDS-PAGE to 
determine the structure of released lactoferrin but this technique does not provide any 
information about the secondary structure or activity of lactoferrin. Therefore investigation 
into the effect of PCL processing conditions on the structural integrity of lactoferrin 
molecules is highly recommended. 
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GENERAL DISCUSSION AND FUTURE DIRECTION 
 
 
 
 
 
  
104 
 
1. Introduction 
The aim of this thesis was to investigate the potential for using polycaprolactone (PCL) as 
a matrix for controlled drug delivery for the intra-vaginal treatment of curable sexually 
transmitted infections. Metronidazole and doxycycline, separately and combined, were 
used because vaginal delivery of these agents would be beneficial in the treatment of 
bacterial vaginosis, gonorrhea and pelvic inflammatory diseases. The use of PCL for the 
delivery of a model macromolecule (lactoferrin) was investigated because macromolecular 
drugs, such as monoclonal antibodies and recombinant proteins, are in development for 
the treatment and prevention of STIs. There are a variety of intravaginal formulations 
available in the market for the treatment of STIs, but these are gels, creams, pessaries 
that require daily insertion. There are a small number of IVRs available commercially but 
these are for delivery of hormones for contraception and treatment of menopausal 
symptoms. This thesis draws attention to the potential use of PCL in intravaginal delivery 
of agents for the treatment of STIs.  
2. PCL matrices for the delivery of different types of drugs  
Many polymers have been tested for their potential use for intravaginal delivery but they all 
have some limitations, for example most of them can deliver only hydrophobic drugs, have 
a high processing temperature and are almost impermeable to macromolecular drugs. 
PCL on the other hand can deliver a wide variety of drugs molecules, including hydrophilic, 
hydrophobic and macromolecular structures, and has a low processing temperature which 
is advantageous for thermolabile drugs. This thesis firstly focused on metronidazole, a 
broad spectrum antibacterial having antimicrobial activity against most Gram-negative and 
Gram-positive anaerobic bacteria and used for the treatment of vaginal infections such 
bacterial vaginosis and trichomoniasis1. The standard oral treatment involves the use of 
metronidazole with an initial induction therapy for 7 days but a long-term maintenance 
regimen of metronidazole is advised. Oral administration of metronidazole is often 
associated with gastrointestinal adverse effects such as nausea, anorexia and 
occasionally vomiting and occasionally a bitter or metallic taste. Gastrointestinal side 
effects are reported to be less common with vaginal administration using the gels, creams 
and pessaries that are currently available, so long term vaginal delivery for the treatment 
of bacterial vaginosis could be very useful. Doxycycline is recommended for the treatment 
of chlamydial and gonococcal infection2,3, with gastrointestinal side effects such as 
nausea, vomiting and mild diarrhoea being common, but it has not previously been 
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investigated for vaginal delivery. Metronidazole and doxycycline in combination are used 
for the treatment of pelvic inflammatory disease4, with treatment being a minimum of 2 
weeks in length.  
In addition to studying the effect of processing and solvents on polymer characteristics, 
their effect on drug activity must be considered, so those aspects were included in this 
thesis. The amount of metronidazole and doxycycline released each day, both alone 
(Chapter 2 and 3) and in combination (Chapter 4), was more than the minimum inhibitory 
concentration against the main causative agents of bacterial vaginosis, gonorrohea and 
pelvic inflammatory diseases. Furthermore, the drugs retained high antibacterial activity 
after being loaded into and released from the polymer. It should be noted that these 
estimates were based on a single SVF pH value, and on the fact that the SVF turnover in 
the vagina of ‘normal’ women is said to be 8-10 mL/day, however other factors such as 
change in vaginal environment during menstruation, ageing and diseased conditions were 
not considered in this thesis. Therefore, it is recommended that before drawing any final 
conclusion further investigation is required to determine the extent to which these factors 
can alter the formulation, dosage and release profile. 
In Chapter 2 the low incorporation efficiency of metronidazole was due to it dissolving and 
being removed in the ethanol used during the manufacturing process, and PEG only 
partially improved this, so during the study of doxycycline the step causing drug loss was 
omitted. This achieved 100% incorporation efficiency without losing any porous properties 
of the polymer (Chapter 3). A combination of two different drugs for treatment purposes 
could be an alternative that can enhance the spectrum of activity. Combinations of 
different drugs with different modes of action through vaginal rings have been applied 
previously in the study of HIV prevention, i.e. dapivirine with darunavir in a silicone IVR5 
and tenofovir with nevirapine in PCL matrices6. This thesis describes the first investigation 
of a combination of drugs for intravaginal drug delivery in the form of IVRs for the 
treatment of sexually transmitted infections, combining metronidazole with doxycycline for 
the treatment of pelvic inflammatory disease (Chapter 4). 
Macromolecular drugs of biotechnological origin have been studied for the treatment and 
prevention of STIs such as Enfuvirtide, 2F5 and recombinant proteins gp160, gp140 and 
gp417-9, and an efficient polymeric delivery system is needed that can deliver 
macromolecules such as these.  So experiments to investigate the efficiency of PCL for 
the delivery of a macromolecule are described in this thesis (Chapter 5). Lactoferrin was 
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used as the model drug because of its macromolecular nature and its reported activity 
against many infections. Lactoferrin was successfully loaded, and the ability to ensure that 
it did not exceed 37°C during processing was an important aspect of the potential value of 
PCL in delivery. However, the solvent used during processing, acetone, may not be 
appropriate for proteins as it may alter their structure, and although the molecular size of 
lactoferrin was unchanged further work is required to determine whether the secondary 
structure and/or activity is affected.  
3.  PCL as a potential material for the IVRs  
A particularly important aspect of any matrix that is going to be used in or on a human 
being is biocompatibility with the appropriate tissues. Leachates from blank PCL matrices 
were tested for biocompatibility in terms of toxicity to vaginal cells and a key member of 
the normal vaginal flora. Data in this thesis (Chapter 3) provides evidence that these 
polymers are expected to be safe for vaginal drug delivery with no toxic effect on the 
vaginal cell line or Lactobacillus jensenii.  
It is well established that IVRs are widely preferred as a vaginal preparation when 
compared to  creams10,  a diaphragm11 and a vaginal patch12. Women generally report 
being satisfied with IVRs and would continue to use them or recommend them to 
others13,14. The main concern about the use of IVRs tends to be some discomfort 
experienced by some women due to presence of the ring inside the vagina. The use of a 
soft polymer is also important to avoid pressure-induced vaginal lesions that can increase 
the chance of infection. This can be minimized by careful selection of the polymer, by 
choosing a polymer that is soft but still has the efficiency to deliver drugs over a long 
period of time. So in this thesis PCL was found to be a potential polymer because during 
the texture analysis (Chapters 2-5) PCL was found to be a softer material when compared 
with the Nuvaring®, which is commercially available polyethylene acetate IVR.  
While PCL appears to be soft enough to be a suitable material for IVRs, all testing in this 
thesis involved cylinders of PCL matrix. Further investigation is required to determine 
whether it is flexible enough to be moulded into a circular IVR and how they perform in 
terms of drug loading and release in the complete form. Future work could also further 
investigate the blending of PCL with suitable polymers because, as shown herein with 
PEG (Chapter 2), other polymers can adjust the mechanical properties of the polymer for 
the further development of IVRs or PCL. As PEG at higher loading lead to increased 
fragility of the matrices it is recommended that PEG is not likely to be of particular interest 
107 
 
in this regard. Other modifications can be done to increase the flexibility of PCL in the form 
of coating it with a flexible polymer with delivery windows or the use of PCL in the form of 
pods with in a flexible ring. 
4. In vivo activity testing 
All tests in this thesis were performed in vitro. This included the experimentation to check 
for PCL leachate toxicity to human vaginal cells and normal commensal vaginal bacteria, 
and also assays for antibacterial activity of the metronidazole and doxycycline after 
release from the PCL matrices. Although the cell studies are a cheap and convenient way 
to check for indications of toxicity, further in vivo experimentation is required in order to 
progress PCL as a polymer for IVRs. The preliminary data presented here can help with 
deciding future experimental design but does not conclude whether the matrix can be used 
safely. Additionally, as doxycycline has not previously been delivered through the 
intravaginal route some basic pharmacokinetic information of drug absorption and safety of 
doxycycline from the vagina is required. Therefore an animal model is strongly 
recommended to check the safety and pharmacokinetic behaviour of drug-loaded PCL 
IVRs. In the literature various models such as sheep, rabbit, pig and macaque monkey are 
recommended to check the suitability of the vaginal products15,16 but careful selection of 
any model is essential to ensure a close correlation between human and animal vaginal 
anatomical characteristics. 
In vivo testing is also required for consideration of ring softness, diameter and flexibility 
because these are important factors in determining acceptability and adherence to 
treatment regimes. As the ultimate aim of the IVRs is to make the therapy convenient and 
acceptable to patients, the optimization of PCL physical characteristics is essential. So, 
following in vivo animal studies, clinical trials would be required to check the suitability, 
safety and acceptability of PCL IVRs. 
5. Conclusion 
In this thesis PCL has been proven to be a potential material for the controlled release of 
antibacterial agents, individually and in combination, for the treatment of STIs as well as 
for the delivery of macromolecules through the intravaginal route. By manipulating the 
production method, 100% drug loading has been obtained. This is accompanied by slow 
release profiles that provide an initial burst release and subsequently maintain daily drug 
release at a higher level than that required to kill the main causative pathogens 
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responsible for the diseases. This sustained period of release continued for the full 12 – 14 
days of the experiments and was only reduced in length when PEG was added into the 
polymer matrix, which suggests that it should be possible to create a PCL IVR that is 
suitable for single insertion at the start of 1 to 2 week duration of therapy. PCL was found 
to be a safe material for the intravaginal delivery in cell culture experiments, and the soft 
nature of the polymer makes it likely to be a highly acceptable material to women in terms 
of comfort for vaginal use. More work need to be done to improve the flexibility of the PCL 
without compromising the other favourable properties of the polymer. The improvement in 
design of the PCL IVR by covering it with flexible material or use of PCL as an insert is 
recommended.  
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